2024 June

Archive for June, 2024

Move Over, Genghis Khan. Many Other Men Left Huge Genetic Legacies – Smithsonian Magazine

June 25th, 2024

Earthwork Portrait of Genghis Khan Christophe Boisvieux/Corbis

Since a 2003 study found evidence that Genghis Khans DNA was present in about 16 million men alive at the time, the Mongolian rulers genetic prowess has stood as an unparalleled accomplishment. But he isnt the only man whose reproductive activities still show a significant genetic impact centuries later. A 2015 study published in the European Journal of Human Genetics found that a handful of other men had prolific lineages, too.

To identify those lineages, the geneticists analyzed the Y chromosomes of more than 5,000 men from 127 populations spanning Asia, wrote Nature News Ewen Callaway in 2015. The Y chromosome is a part of the human genome handed down only from father to son. They found 11 Y-chromosome sequences that were each shared by more than 20 of the analyzed subjects. Chalk down one of those as Genghis Khans, and that leaves ten other men who initiated long-lived and widely spread family trees.

When he ruled during the 13th century, Genghis Khan presided over land that spanned from the Pacific coast of China to the Caspian Sea. Historians dont know exactly how many children Genghis Khan sired, but many agree his lineage is broad. In 1260, Persian historian Ata-Malik Juvaini wrote: Of the issue of the race and lineage of Chingiz [Genghis] Khan, there are now living in the comfort of wealth and affluence more than 20,000.

Mongol rulers such as Genghis Khan could have spread their genes widely, because of rapes during conquests and because the khans had access to many women in the areas they ruled, Oxford University geneticist Chris Tyler-Smith told Nicholas Wade of the New York Times in 2003.

Genghis Khans sons may have followed in their fathers footsteps and had large harems. Tushi, the emperors oldest son, had 40 sons himself, per the New York Times.

So, who were the other super-fertile fathers? One genetic sequence is attributed to Giocangga, the grandfather of the founder of the Qing dynasty. His Y chromosome was linked in a 2005 study to 1.5 million men in modern northern China. This large number likely resulted from his descendants taking many wives and concubines.

The other nine men are currently mysteries. Yet, by assuming they lived in the area where their genomes were most commonly found and by studying mutations in the genetic sequences, scientists suggest they originated throughout Asia between 2100 B.C.E. and 700 C.E., per Nature News.

According to Nature News, the founders who lived at the earlier end of this range, between 2100 B.C.E and 300 B.C.E., were part of both agricultural and nomadic cultures. They lived during the emergence of hierarchical, authoritarian societies in Asia. And the three lineages connected to more recent times, including those linked to Genghis Khan and Giocangga, were associated with nomadic peoples in Mongolia and northeast China.

Large genetic legacies are not confined to that part of the globe. According to a 2006 study in the American Journal of Human Genetics, 1 in 12 Irishmen worldwide can trace their heritage back to a single individual. That man may be a fifth-century Irish warlord dubbed Niall of the Nine Hostages, who could have as many as three million direct male descendants in modern times.

Genetic studies published in the last few years have continued to reveal more information about the heritage of peoples around the world. From uncovering the genetic history of the Viking age to confirming the origins of the Swahili people and pinpointing Neanderthal genes in modern populations, techniques analyzing ancient DNA have opened another window to understanding how genes flowed in the past.

As far as the nine unknown founders with impressive genetic lineages, more research is needed to discern their identities. But one thing is certain: Genghis Khan has never been the only big kid on the genetic block.

Get the latest stories in your inbox every weekday.

Excerpt from:
Move Over, Genghis Khan. Many Other Men Left Huge Genetic Legacies - Smithsonian Magazine

Comments Closed|

Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy Development – CGTLive

June 25th, 2024

"Gene therapy is the ultimate team sport within science, it's one of the reasons I love it, not only in terms of the stages of development of the product, but also often developing the gene or cell therapy itself. You need to figure out how you're going to deliver it, what's the route of administration? What's the capsid, or delivery vehicle that you're going to use? How do you design the transgene? How do you consider an animal model? That naturally lends itself to bringing together a lot of different expertise.

As gene and cell therapies grow in prevalence, continuing early research in the field is paramount to improving multiple aspects of these novel therapies. A number of researchers from Mass General Brigham (MGB) presented work dealing with new technologies and new methods aiming to improve gene and cell therapy and its delivery to different tissues, particularly the brain, atthe American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland.

CGTLivespoke with Nathan Yozwiak, PhD, head of research, Cell and Gene Therapy Institute, MGB, to learn more about the research presented at the meeting and other research that MGB is engaged in with cell and gene therapy. He discussed the MGB Gene and Cell Therapy Institute and emphasized its value as a resource for sponsors, investigators, and researchers involved with gene and cell therapies to hopefully speed up the process of developing these therapies. He stressed the importance of collaboration when developing and then assessing gene and cell therapies and how administrating these therapies is a big collaborative lift.

More:
Nathan Yozwiak, PhD, on Collaboration for Cell and Gene Therapy Development - CGTLive

Comments Closed|

Berlin Center for Gene and Cell Therapies kicked off in Berlin – The Palm Bayer

June 25th, 2024

Berlin, Germany, June 21, 2024 Today Bayer AG, together with Charit Universittsmedizin Berlin, presented plans for the construction of the Berlin Center for Gene and Cell Therapies. The project is being substantially financed and supported by Germanys Federal Government as well as the State of Berlin. The aim of the joint project is to bring these groundbreaking technologies to patients more quickly while creating a leading biotech ecosystem for innovative therapies in Berlin.

The potential for cell and gene therapies (CGTs) is considered to be enormous. By targeting diseases at the genetic and cellular level, CGTs could offer options to people for whom conventional therapies have failed or where no effective treatment is currently available.

In order to translate basic research into benefits for patients faster, Charit and Bayer will establish the Berlin Center for Gene and Cell Therapies on the Bayer campus at Berlin Nordhafen. The center will support start-ups bringing their innovative approaches in the area of cell therapies and gene therapies into clinical development. To achieve this, the center will include a so-called incubator with fully equipped laboratory space and a production area certified according to the standards of good manufacturing practice (GMP). Incubators are facilities that accompany start-ups developing their innovative ideas and helping them build viable business models. These early-stage companies will receive advice on regulatory requirements, clinical trials, patent rights and business development. To operate the incubator, Bayer and Charit will establish a joint public-private, non-profit company with limited liability. Charit will own 67 percent of this company, with Bayer owning the remaining 33 percent.

The Berlin Center for Gene and Cell Therapies will bring together research, development and the manufacturing of cell therapies and gene therapies in the heart of Berlin. Purposely embedding it within the Berlin ecosystem, a European capital with a large number of biomedical and healthcare facilities, it is intended to become a creative and interactive hub for biotech innovations in the area of CGT. The project is funded by both the Federal Ministry of Education and Research and the State of Berlin. Construction is planned to begin in 2025.

Olaf Scholz, Federal Chancellor of Germany: "With the kick-off of the new translation center, we are also celebrating a unique form of collaboration between science, industry and politics. This institution will become the core of an entire organism of gene and cell-based therapies. To achieve this, we need scientists and entrepreneurs who see both the smallest details in the cell nucleus as well as the big picture: the medicine of the future that provides answers to the big questions that Rudolf Virchow already posed. Here in Germany we have both: bold research and innovative companies. I wish you every success with this visionary project!"

Bettina Stark-Watzinger, Federal Minister of Education and Research: Gene and cell therapies offer a tremendous opportunity for more targeted and therefore better treatment of patients. Currently, however, the path from the research laboratory to the patient's bedside often still takes too long. With the translation center for gene and cell therapies, we are now taking a big step forward in Germany. Science and industry are coming together in one location to turn ideas into reality and to help translate scientific findings into medical practice more quickly through spin-offs and start-ups. As an essential component of the National Strategy for Gene and Cell Therapies, the Federal Ministry of Education and Research is supporting the establishment of the Center with around

80 million euro. In doing so, we are once again strengthening Germany's position as a leading location for biomedical innovations.

Prof. Dr. Karl Lauterbach, Federal Minister of Health: Targeted gene therapies, personalized cancer vaccines and novel antibody-drug conjugates, together with artificial intelligence, will open a new era in medicine and entirely new prospects for patients. These revolutionary treatment approaches place high demands on laboratories, hospitals and doctors. This joint project of Bayer and Charit is an ideal partnership to learn together and make rapid progress.

Bill Anderson, Chairman of the Board of Management (CEO) of Bayer AG: Despite great advances in research and technology, there are still many diseases that are without cure and which affect the lives of millions. To these people, cell and gene therapies offer great hope. Only through close partnerships across borders, new approaches and quick action can we make real progress towards our objective of curing diseases that were long considered incurable.

Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayers Pharmaceuticals Division: The close proximity between research and production within the Berlin Center for Gene and Cell Therapies will be unique in Germany. Together with the Charit we want to help translate scientific knowledge in the area of cell therapies and gene therapies into innovative treatment approaches for patients as quickly as possible. With the Berlin Center for Gene and Cell Therapies, it is our vision to establish a biotech ecosystem, which unites different players, providing international appeal way beyond the city of Berlin.

Prof. Dr. Heyo K. Kroemer, Chief Executive Officer of Charit: Cell therapies and gene therapies represent a major medical advance; they can help where conventional methods reach their limits. As these are highly innovative drugs, their development, however, is much more complex than that of other medicines. If we want to bring these therapies to patients as quickly as possible, we need to take new routes. With the intensified partnership between Charit and Bayer, we want to initiate structural development to bring Berlin to the forefront of this pioneering technology both nationally and internationally. In doing so, we also create and maintain value and thus jobs in the country. This is a big step in Berlin, for Berlin and for Germany.

Astrid Lurati, Chief Financial and Infrastructure Officer of Charit: "As part of this project, the two partners Charit and Bayer are combining their respective expertise to further advance the developments in the field of gene and cell therapy both nationally and internationally. This approach is unique in Germany and demonstrates the innovation power of Berlin and its major healthcare players in their efforts to reimagine the medical care of tomorrow already today. The extensive support, which we are receiving both from the State of Berlin as well as the Federal Government underlines the importance of this project. With the Berlin Center for Gene and Cell Therapies we are breaking new ground together and I would like to thank everyone involved for the excellent cooperation."

Kai Wegner, Governing Mayor of Berlin: Berlin is a strong and leading location for science, research and medicine and therefore for the healthcare industry as a whole. The newly emerging translation center for gene and cell therapies is an excellent example of this. The State of Berlin has supported this lighthouse project from the beginning as we are convinced of the potential that gene and cell therapies provide. The collaboration between Charit and Bayer in one of the most innovative areas of medicine is a clear signal that together we can make Berlin and Germany a pioneer in this field. It is our common goal to help more patients with the most modern therapies, where todays medicine still reaches its limits. In addition, the location provides an excellent environment, which we will continue to strengthen by further developing the Bayer site into a life science campus.

Franziska Giffey, Mayor and Berlin State Senator for Economic Affairs, Energy and Public Enterprises: The close collaboration between companies and the excellent research in the city is a recipe for success to achieve our goal of making Berlin the number one innovation hotspot in Europe. With the Bayer and Charit translation center for gene and cell therapies we are moving a big step closer to reaching this goal. It brings together two internationally renowned medical pioneers and will benefit from its location in Berlin, one of the most successful start-up ecosystems in the world. The new center has enormous economic potential and will attract talent and investment. This is very good news for the growing business location of Berlin.

The Berlin Center for Gene and Cell Therapies is being developed by iQ spaces, a project developer specialized in laboratory real estate, on the Bayer campus at Berlin Nordhafen. Across 18,000 sqm, the ten-story building is divided into an incubator with fully equipped laboratory and office space to accommodate 15 to 20 start-ups in various stages of development, as well as a GMP-certified manufacturing facility for the development of cell and gene therapies up to clinical phase II. The building was designed by the architectural firm HENN.

About cell therapies and gene therapies Cell therapies and gene therapies (Advanced Therapy Medicinal Products, ATMPs) are among the most important innovations in the healthcare sector. They have the potential to fundamentally change the treatment of cancer, autoimmune diseases, neurodegenerative diseases and many rare genetic diseases. The novel therapies are based on genes, tissues or cells and therefore often contain living components. These products, which are therefore also referred to as living drugs, can be better tailored to individual patients than traditional medicines and are particularly suitable for the treatment of diseases that were previously untreatable or difficult to treat. Although several hundred clinical studies for the development of cell therapies and gene therapies are currently ongoing, only a small number of such products is currently approved in Europe. The goal of Bayer and Charit is for the Berlin Center for Gene and Cell Therapies to bridge this translation gap.

About Charit Universittsmedizin Berlin With more than 100 departments and institutes across four campuses and 3,293 beds, Charit Universittsmedizin Berlin is one of Europes largest university medical centers. At Charit, the areas of research, teaching, and medical and patient care are closely interconnected. Averaging about 20,000 employees Charit-wide and some 23,500 across the entire group of companies, Berlins university medicine organization remained one of the capital citys largest employers in 2023. Charit is a leader in diagnosis and treatment of particularly severe, complex, and rare diseases and health conditions. A medical school and university medical center in one, Charit enjoys an outstanding reputation worldwide, combining first-class patient care with excellence in research and innovation, state-of-the-art teaching, and high-quality training and education. Everything Charit does revolves around people and their health. Charit pursues translational research in which scientific findings are applied to prevention, diagnostics, and treatment and clinical observations inform new approaches in research in turn. At Charit, the goal is to actively help shape the medicine of the future to benefit patients. https://www.charite.de/en/

About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, Health for all, Hunger for none, the companys products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to http://www.bayer.com.

Find more information at https://pharma.bayer.com/ Follow us on Facebook: http://www.facebook.com/bayer

Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayers public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Follow this link:
Berlin Center for Gene and Cell Therapies kicked off in Berlin - The Palm Bayer

Comments Closed|

Top FDA official Peter Marks overruled staff to approve Sarepta gene therapy – STAT

June 25th, 2024

For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy.

On Thursday evening, the FDA announced it expanded the approval of Elevidys, Sareptas Duchenne gene therapy, to cover nearly all patients, regardless of age or wheelchair status, despite the fact that the drug failed a large, Phase 3 trial last year.

That decision, documents concurrently released by the agency show, was made almost exclusively by Peter Marks, the agencys director of the Center for Biologics Evaluation and Research. He overruled three review teams and two top lieutenants, who wrote that the data Sarepta submitted cast significant uncertainty regarding the benefits of treatment.

STAT+ Exclusive Story

Already have an account? Log in

Get unlimited access to award-winning journalism and exclusive events.

See original here:
Top FDA official Peter Marks overruled staff to approve Sarepta gene therapy - STAT

Comments Closed|

Cell and Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15.5% by 2034: Visiongain – GlobeNewswire

June 25th, 2024

Visiongain has published a new report entitled Cell & Gene Therapy Cold Chain Logistics Market Report 2024-2034: Forecasts by Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra-Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others), by Services (Transportation, Storage, Packaging), by Mode of Transport (Air Transport, Ground Transport, Water Transport), by Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others), by End-users (Biopharmaceutical and Biotechnology Companies, Academic & Research Institutes, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global cell and gene therapy cold chain logistics market is estimated at US$1,877.3 million in 2024 and is projected to grow at a CAGR of 15.5% during the forecast period 2024-2034.

Escalating Adoption of Cell Therapies and Gene Therapies is Driving the Demand for Cold Chain Logistics

Recent advancements in cell and gene therapy have led to the approval of numerous novel treatments for conditions such as blood disorders and cancer. On March 14, 2024, the FDA granted approval to Bristol Myers Squibb's Breyanzi, marking it as the inaugural CAR T cell therapy for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic leukaemia. Additionally, on February 17, 2024, the FDA granted accelerated approval to Iovance Biotherapeutics' Amtagvi, a one-time cell therapy for unresectable or metastatic melanoma, with ongoing studies to confirm its efficacy. As the adoption of these therapies increases, the demand for proper storage, distribution, and logistics of cell and gene therapy products is expected to rise. Transporting these therapies to various countries requires a highly controlled and regulated process to ensure their safety and efficacy, which will significantly boost the cold chain logistics market.

Download Exclusive Sample of Report https://www.visiongain.com/report/cell-gene-therapy-market-2024/#download_sampe_div

How will this Report Benefit you?

Visiongains 359-page report provides 146 tables and 198 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the cell and gene therapy cold chain logistics market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Cell and Gene Therapy Cold Chain Logistics. Get financial analysis of the overall market and different segments including type, process, upstream, downstream, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing cell and gene therapy cold chain logistics market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Growth in Cancer and Genetic Disorders

Genetic disorders, stemming from abnormalities in genetic makeup and chromosomes, present a range of physical and mental health challenges globally. Disorders like alpha-1 antitrypsin deficiency, cystic fibrosis, beta thalassemia, haemophilia, and sickle cell disease have gained prominence due to factors including heightened awareness, advancements in diagnostic technology, and environmental and lifestyle changes. Low-income nations, in particular, face challenges such as inadequate diets, exposure to environmental toxins, and unhealthy lifestyles, increasing the risk of genetic abnormalities.

The WHO estimates that 5% of the global population carries sickle-cell disease, hemoglobin disorders, or thalassaemia, with over 300,000 babies born annually with severe hemoglobin disorders. Thalassemia, prevalent in regions like the Mediterranean, Middle East, Southeast Asia, and Africa, affects approximately 4.4 out of every 10,000 live births globally, with up to 40% of Southeast Asia's population being genetic carriers. These factors are poised to drive demand for cell and gene therapies in these regions, further emphasizing the necessity for proper transportation and storage of these biotherapeutics.

Increasing Strategic Initiatives Among Market Players Are Shaping the Industry's Future

The intricate processes involved in manufacturing, storing, and delivering cell and gene therapies demand a high level of expertise, specialized infrastructure, and adherence to stringent regulatory standards for global distribution. Major market players, spanning manufacturers to specialized logistics companies, are increasingly pursuing strategic initiatives such as launching new services and products, forging collaborations, and forming agreements to ensure the safe and efficient storage and transportation of these temperature-sensitive biologics. Regulatory bodies are also actively involved, offering crucial support to ensure compliance with international regulations and guidelines for therapeutic transportation. Significant initiatives include AmerisourceBergen's World Courier announcing the implementation of a real-time location monitoring solution across its multi-use packages in April 2023, aimed at enhancing shipment visibility during transit on a global scale.

Get Detailed ToC https://www.visiongain.com/report/cell-gene-therapy-market-2024/

Where are the Market Opportunities?

Stringent Government Regulations for Cell and Gene Therapy Transportation Are Expected to Boost the Market Growth

Stringent government regulations for cell and gene therapy transportation and storage present significant growth opportunities for market players by necessitating strict compliance measures. Companies must adhere to meticulous documentation standards, such as detailed records of temperature monitoring and handling procedures. For example, logistics providers like DHL and UPS offer specialized software to streamline these processes, ensuring regulatory compliance. Validation of cold chain processes is critical, involving extensive studies and costs to confirm the efficacy of temperature-controlled packaging, as seen with services from companies like Pelican BioThermal. Quality control measures, including audits and real-time monitoring, are essential for maintaining product integrity, with firms like Cryoport exemplifying strict adherence to these standards, thereby ensuring the safe and effective delivery of biologic products.

Surge in Cell and Gene Therapies Pipeline

The cell and gene therapy landscape is witnessing a surge in clinical pipeline strength and product approvals, propelled by technological advancements and substantial investments in research and development. This momentum is driving a significant increase in clinical studies focused on cell and gene therapeutics across various medical indications, extending beyond genetic disorders. Major biopharmaceutical companies are actively exploring the potential of these therapies for a diverse range of conditions.

Recent clinical findings have highlighted promising outcomes, particularly in areas like autoimmune disorders, where therapies such as regulatory T cells and mesenchymal stem cells have shown potential as future drug candidates, with approximately 1000 cell and gene therapies currently in the product development pipeline. For instance, on 4 January 2024, AbbVie and Umoja Biopharma announced two exclusive agreements to develop CAR-T cell therapies using Umoja's VivoVec platform. In future approval of these temperature sensitive biotherapeutics is estimated to increase necessity for temperature controlled and specific storage and transportation of these biologics to patients and healthcare providers in various parts of the globe.

Competitive Landscape

The market is highly fragmented with a lot of companies and products available for cold chain logistics of cell and gene therapies. The major players in the market are Cencora, Inc., Cardinal Health, Catalent Inc., Thermo Fisher Scientific Inc., Marken (a UPS Company), A.P. Moller Maersk, CryoPort Inc., DHL, FedEx, Arvato SE, NMDP BioTherapies, BioLife Solutions Inc., BioStor Systems Inc., Yourway, Atelerix Ltd., Nordic Cold Chain Solutions, MasterControl Solutions, Inc., TrakCel, Modality Solutions, and sedApta s.r.l. Companies focusing on the cell and gene therapy cold chain market utilize specialized solutions, integrated logistics, and regulatory compliance expertise. Modality Solutions and CryoPort Inc. offer customized cold chain processes, whereas DHL, FedEx, and Marken provide temperature-controlled global logistics services. Cardinal Health and Modality Solutions excel in regulatory compliance, assisting clients in navigating industry regulations to ensure the safe transportation of therapies.

Recent Developments

To access the data contained in this document please emailcontactus@visiongain.com. Avoid missing out by staying informed order our report now.

To find more Visiongain research reports on the Pharma sector, click on the following links:

Do you have any custom requirements we can help you with?Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:contactus@visiongain.com

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicatedmarket research reportsoffer a bespoke piece of market intelligence customised to your very own business needs.

Contact

Visiongain Reports Limited Telephone: +44 (0) 20 7336 6100 Email:contactus@visiongain.com Web:www.visiongain.com

Read more:
Cell and Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15.5% by 2034: Visiongain - GlobeNewswire

Comments Closed|

Phase 3 CIFFREO Trial of DMD Gene Therapy Misses Primary End Point – AJMC.com Managed Markets Network

June 25th, 2024

The CIFFREO trial (NCT04281485) of fordadistrogene movaparvovec, an investigational mini-dystrophin gene therapy for Duchenne muscular dystrophy (DMD) developed by Pfizer, did not meet its primary end point of motor function improvement vs placebo among boys aged 4 to 7 years, the company announced in a press release.1

Improvement in motor function among ambulatory patients, determined by change in North Star Ambulatory Assessment at 1 year post treatment, was the main end point in the study. There were also no significant improvements in key secondary end points, including 10-meter run or walk speed and time to rise from floor.

While the question of gene therapys long-term efficacy remains, it is a promising route of therapy for patients with DMD | Image credit: luchschenF - stock.adobe.com

We are extremely disappointed that these results did not demonstrate the relative improvement in motor function that we had hoped, Dan Levy, MD, PhD, development head for Duchenne muscular dystrophy at Pfizer, said in a statement. We plan to share more detailed results from the study at upcoming medical and patient advocacy meetings, with the goal of ensuring that learnings from this trial can help improve future clinical research and development of treatment options that can improve care for boys living with Duchenne muscular dystrophy. We are grateful for the boys, their families, advocates, and the investigators who have participated in this research and the continuing effort to advance treatment options for this debilitating disease.

While the overall safety profile of the treatment was largely manageable in the CIFFREO trial, the study has paused dosing in its crossover portion due to a fatal serious adverse event in the phase 2 DAYLIGHT trial (NCT05429372), a multicenter, single-arm study evaluating safety and dystrophin expression after treatment with fordadistrogene movaparvovec in boys aged 2 to less than 4 years.2 In a community letter, Pfizer announced the loss of the patient but was still working to understand the its cause at the time.3

In the CIFFREO trial, adverse events were generally mild to moderate, and serious treatment-related adverse events generally responded to clinical management.1

DMD, the most common form of muscular dystrophy in children, is characterized by muscle breakdown over time due to patients without a functional dystrophin gene.4 Patients with DMD produce little to no dystrophin, which is a crucial protein for muscle strength.

Gene therapy is a promising area of research for patients with DMD, with the goal being to stabilize the disease by inducing production of a shortened but functional version of dystrophin. Lost muscle cannot be brought back by gene therapy, so it is not a curative therapy, but gene therapies have demonstrated promise for symptom mitigation and even strength improvement among some children.

The first gene therapy for DMD was FDA approved in June 2023 for patients aged 4 through 5 years.5 Delandistrogene moxeparvovec-rokl (Elevidys) was approved through the FDAs accelerated approval pathway and remains the only approved gene therapy for this patient population. The treatment was given the green light based on data from a randomized trial establishing increased expression of micro-dystrophin protein in treated patients.

While the question of gene therapys long-term efficacy remains, it is a promising route of therapy for patients with DMD.4 Alternative approaches to delivery are also being studied, with an aim of better targeting the muscles that need dystrophin or producing versions of dystrophin that are more functional compared with current gene therapies.

References

1. Pfizer provides update on phase 3 study of investigational gene therapy for ambulatory boys with Duchenne muscular dystrophy. News release. Pfizer. June 12, 2024. Accessed June 19, 2024. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-phase-3-study-investigational-gene

2. Study of fordadistrogene movaparvovec in early stage Duchenne muscular dystrophy. ClinicalTrials.gov. Updated April 4, 2024. Accessed June 19, 2024. https://www.clinicaltrials.gov/study/NCT05429372

3. Update on Pfizers phase 2 gene therapy trial for Duchenne. Parent Project Muscular Dystrophy. May 7, 2024. Accessed June 19, 2024. https://www.parentprojectmd.org/update-on-pfizers-phase-2-gene-therapy-trial-for-duchenne/

4. Gene therapy for Duchenne muscular dystrophy. Childrens Hospital of Philadelphia. Accessed June 19, 2024. https://www.chop.edu/gene-therapy-duchenne-muscular-dystrophy

5. FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy. News release. FDA. June 22, 2023. Accessed June 19, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy

Continue reading here:
Phase 3 CIFFREO Trial of DMD Gene Therapy Misses Primary End Point - AJMC.com Managed Markets Network

Comments Closed|

FDA Approves Sarepta’s DMD Gene Therapy Elevidys for Expanded Indication – CGTLive

June 25th, 2024

This is a developing story and will be updated with new information as it becomes available.

The FDA has approved Sarepta Therapeutics delandistrogene moxeparvovec-rokl (marketed as Elevidys), an adeno-associated virus (AAV) vector-based gene therapy for patients with Duchenne muscular dystrophy (DMD), for an expanded indication in the disease.1 The therapy is now approved for ambulatory patients (via traditional approval) and nonambulatory patients (via accelerated approval) with a confirmed mutation in the DMD gene who are 4 years of age or older and who do not have any deletion in exon 8 or exon 9 in the gene.

Representing many years of dedicated research, development, investment and creative energy, the expansion of the Elevidys label to treat Duchenne patients aged 4 and above, regardless of ambulatory status, is a defining moment for the Duchenne community," "Today also stands as a watershed occasion for the promise of gene therapy and a win for science, Doug Ingram, JD, the president and chief executive officer of Sarepta, said in a statement.1 At this pivotal moment, I want to give warm thanks to Drs. Jerry Mendell and Louise Rodino-Klapac for their dogged, 20-year pursuit of a gene therapy to treat this ruthless and life-robbing disease, to the FDA for following the scientific evidence to speed delivery of a therapy for a life-threatening rare disease to waiting patients, and to the many clinical investigators and courageous Duchenne families who have participated in the multiple studies that led to this important day.

Elevidys was originally granted FDA approval under an accelerated approval pathway for a more limited indication on June 22, 2023.2 That original decision limited the therapy's use to ambulatory patients aged 4 through 5 years withDMD and a confirmed mutation in theDMDgene, excluding patients with any deletion in exon 8 and/or exon 9. Today's decision, which was based on the agency's confirmation of functional benefits, additionally converts the accelerated approval to a traditional approval for patients who are ambulatory. Although it also expands eligibility to nonambulatory patients, the therapy remains under an accelerated approval for patients who are nonambulatory.1 Sarepta noted that ongoing approval for patients who are nonambulatory may depend on the results of ENVISION (Study SRP-9001-303), a phase 3 confirmatory clinical trial evaluating the gene therapy in patients with DMD who are nonambulatory or older and ambulatory.

Todays expansion of the Elevidys label represents the culmination of my 50-year pursuit of a treatment for Duchenne patients and, along with my colleague Dr. Louise Rodino-Klapac, a nearly 20-year effort to optimize and develop a gene therapy that could be safely and effectively delivered to muscle, Jerry Mendell, MD, the coinventor of Elevidys and the senior advisor for Medical Affairs at Sarepta added to the statement.1 The initial approval of Elevidys was a significant milestone, and the expanded indication means clinicians now have a treatment option for the great majority of boys and young men living with Duchenne. This expansion speaks to the success of the science, the evidence, and the improvements in the trajectory of the disease we have seen to date across studies.

Elevidy's original approval in 2023 was based upon data from the phase 1/2 SRP-9001-101 (NCT03375164) study, the phase 2 SRP-9001-102 study, and the phase 1 ENDEAVOR study (SRP-9001-103; NCT04626674).2 Changes in expression of microdystrophin, a surrogate end point, informed the approval. Furthermore, in the 20-patient cohort 1 of ENDEAVOR, announced in July 2022, findings showed that SRP-9001-treated patients improved 4 points from their pre-therapy baselines on the North Star Ambulatory Assessment (NSAA) compared with a propensity-weighted external control group (P < .0001) over 1 year.3 These patients demonstrated a 3.8-point (unadjusted means) and 3.2-point (least squared means) improvement that diverged from the natural history of DMD over time.

More recently, results from EMBARK, another phase 3 clinical trial (NCT05096221) evaluating Elevidys in DMD, were presented atthe American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland, by Damon Asher, MS, PhD, senior director of global medical affairs at Sarepta Therapeutics.4 Notably, EMBARK failed its primary end point. However, key secondary endpoints of change in time to rise (TTR) and time to walk/run 10 meters (10MWR) had small but significant differences from placebo, with a least square mean (LSM) difference of -.64 seconds (standard error [SE], 0.21; P = .0025) on TTR and an LSM of -0.42 seconds (SE, 0.15; P = .0048) on 10MWR.5 A composite, prespecified global statistical test including NSAA, TTR, 10MWR, Stride Velocity 95th Centile, 100MWR, and ascend 4 steps test was statistically significant compared with placebo (P = .0044).4

What's really going to tell the story is as these patients are followed over longer periods of time," Asher told CGTLive during the conference. "Theres a lot of challenges in showing efficacy, even with something that may be fairly efficacious, over such a short period of time."

Read more from the original source:
FDA Approves Sarepta's DMD Gene Therapy Elevidys for Expanded Indication - CGTLive

Comments Closed|

FDA expands approval of first gene therapy for rare form of muscular dystrophy – KDRV

June 25th, 2024

(CNN) The US Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular dystrophy to be used in most people who have the disease and a certain genetic mutation.

Last year, the drug Elevidys, from the biotech company Sarepta Therapeutics was approved to treat only children ages 4 and 5 with Duchenne muscular dystrophy, one of the most severe forms of inherited muscular dystrophies, who have a confirmed mutation in a gene called DMD that is associated with muscle strength.

The FDA announced Thursday that it had given traditional approval for Elevidys for ambulatory people 4 and older with a confirmed mutation in the DMD gene and accelerated approval for non-ambulatory people 4 and older with this mutation. Theres not enough data on safety to support its use in children under 4, the agency says.

Elevidys, given as a one-time intravenous infusion, costs about $3.2 million per patient, making it among the most expensive drugs in the world. Although eye-popping, such aprice tagisnt out of step with other one-time gene therapies, which have topped$3 million to 4 millionper patient in recent years.

Elevidys was previously approved under the FDAs accelerated approval pathway, which clears medicines for diseases where theyre urgently needed based on data suggesting that theyre likely to confer clinical benefits. The drug has been closely monitored since that approval, and in October, Sarepta Therapeutics released results from a confirmatory trial showing that the therapy missed its primary goal a measure of how well kids can move but was successful on a number of secondary measures.

The approval addressed an urgent unmet medical need and is an important advancement in the treatment of Duchenne muscular dystrophy, a devastating condition with limited treatment options, that leads to a progressive deterioration of an individuals health over time, Dr. Peter Marks, director of the FDAs Center for Biologics Evaluation and Research, said in a news release at the time.

It was the first time a therapy of this nature a one-time treatment that delivers a working copy of a gene to make up for one that leads to disease had been cleared under the accelerated approval framework. The move came after emotionaltestimonialsfrom families at an FDA advisory committee meeting.

Duchenne muscular dystrophy causes progressive muscle weakness that can rob children of their ability to walk by the time theyre teenagers, and many dont live well into their 30s. It primarily affects boys because of the way its inherited, affecting an estimated 1 in 3,300 boys.

The Muscular Dystrophy Association trusts the decision of the FDA, which weighs the risks and benefits of the drug, said Dr. Sharon Hesterlee, chief researcher at the association.

Ultimately, what we want is whats best for our patient community and thats balancing that risk-benefit ratio appropriately, she said.

Potential risks of Elevidys include increases in certain liver enzyme levels and acute serious liver injury. The most common side effects of the drug include vomiting, nausea, increased liver function tests and fever.

Yet a major benefit is that the gene therapy provides another option for people with Duchenne muscular dystrophy, and its administered just once.

There is no cure for Duchenne muscular dystrophy, and outside of Elevidys, treatments are limited. Otherapproachesmay include steroid medications,certaindrugs that change how the muscle cells read the mutated gene, physical therapy or surgery to correct spinal curvature, Hesterlee said.

Right now, themainstandard of care for Duchenne is corticosteroids, like prednisone,although there are some newer drugs available. These kids arestilloften on chronic doses ofsteroidsfor many, many years, she said, adding that the side effects of corticosteroids such as weight gain, behavioral issues and increased risk of bone breakage are not ideal.

Duchenne muscular dystrophy can be difficult to treat, she said, and having more treatment options that are proven to be effective remains important.

Muscle makes up a significant amount of your body mass. So when you have a disease like this, its really impacting a lot of tissue. So anything you do, youre looking at trying to bring back or stop a disease process thats really throughout the body, and its a disease thats progressive, so you lose more and more muscle over time, Hesterlee said.

Thats made it pretty challenging, but weve certainly learned a lot, she said. You cant overlook the fact that these boys are living so much longer and doing so much better. Even 20 years ago, they were dying in their teens, and many of them are now living into their 30s. Theyre going to college; they have girlfriends; some of them have gotten married. These are things that werent happening years ago. So weve made a tremendous amount of progress.

The-CNN-Wire

Link:
FDA expands approval of first gene therapy for rare form of muscular dystrophy - KDRV

Comments Closed|

Lentiviral Vector In Gene Therapy Market Forecasts, Market Trends and Impact Analysis (2024 – 2031) – openPR

June 25th, 2024

Market Overview and Report Coverage

Lentiviral vectors are a type of viral vector used in gene therapy to deliver genetic material into target cells. They are derived from lentiviruses, which are a type of retrovirus known for their ability to integrate their genetic material into the host cell's genome. This integration allows for stable and long-lasting gene expression, making lentiviral vectors an attractive option for gene therapy applications.

The Lentiviral Vector In Gene Therapy Market is expected to grow at a CAGR of 12.30% during the forecasted period. The current outlook for this market is promising, with increasing research and development activities in the field of gene therapy driving the demand for lentiviral vectors. Advances in genetic engineering and gene editing technologies have also expanded the potential applications of lentiviral vectors in treating a wide range of genetic disorders, cancers, and other diseases.

Moreover, the growing globalization of the pharmaceutical and biotechnology industries, along with increasing partnerships and collaborations between companies and research institutions, are further fueling the growth of the Lentiviral Vector In Gene Therapy Market. With ongoing technological advancements and a supportive regulatory environment, the future of lentiviral vectors in gene therapy looks bright, offering hope for patients with currently incurable genetic diseases.

Explore the Full Report Now!: https://www.reportprime.com/lentiviral-vector-in-gene-therapy-r10093

Market Segmentation 2024 to 2031

The Lentiviral Vector In Gene Therapy Market Analysis by types is segmented into:

Retrovirus (RV) Adenovirus (AdV) Adeno-associated Virus (AAV)

Lentiviral vectors are commonly used in gene therapy due to their ability to efficiently deliver genetic material into target cells. Retrovirus (RV) vectors are derived from retroviruses and integrate their genetic material into the host cell genome. Adenovirus (AdV) vectors are based on adenoviruses and provide high levels of gene expression in target cells. Adeno-associated Virus (AAV) vectors are derived from adeno-associated viruses and are known for their safety and ability to infect a wide range of cell types. These vectors play a crucial role in the gene therapy market for various applications.

Get a Sample PDF of the Report: https://www.reportprime.com/enquiry/request-sample/10093

The Lentiviral Vector In Gene Therapy Market Industry Research by Application is segmented into:

Hospital Clinic Research Institution Others

The Lentiviral Vector in Gene Therapy market application is utilized in various sectors including hospitals, clinics, research institutions, and other medical facilities. This technology is being increasingly used in gene therapy to treat genetic disorders and other diseases. Hospitals and clinics are incorporating Lentiviral Vector technology to provide advanced treatment options to their patients. Research institutions are utilizing these vectors in their studies to explore potential therapeutic applications. Other markets also benefit from Lentiviral Vectors for various research and medical purposes.

Inquire or Share Your Questions If Any Before Purchasing This Report: https://www.reportprime.com/enquiry/pre-order/10093

In terms of Region, the Lentiviral Vector In Gene Therapy Market Players available by Region are:

North America: United States Canada

Europe: Germany France U.K. Italy Russia

Asia-Pacific: China Japan South Korea India Australia China Taiwan Indonesia Thailand Malaysia

Latin America: Mexico Brazil Argentina Korea Colombia

Middle East & Africa: Turkey Saudi Arabia UAE Korea

Purchase this Report: https://www.reportprime.com/checkout?id=10093&price=3590

What are the Emerging Trends in the Global Lentiviral Vector In Gene Therapy market?

- CRISPR/Cas9 technology: Lentiviral vectors are being used in conjunction with CRISPR/Cas9 gene editing technology to more precisely target and edit genes for therapeutic purposes.

- Cell-specific targeting: Researchers are developing lentiviral vectors that can target specific cell types, improving the efficiency and safety of gene therapy treatments.

- Non-viral gene delivery systems: Emerging non-viral gene delivery systems are being developed as alternatives to lentiviral vectors, potentially disrupting the market.

- Personalized medicine: Increased focus on personalized medicine is driving the development of lentiviral vectors tailored to individual patient needs.

- Regulatory advancements: Regulatory agencies are working to streamline the approval process for gene therapy products, spurring growth in the lentiviral vector market. These trends collectively indicate a positive growth trajectory for the Lentiviral Vector In Gene Therapy market as it continues to evolve and innovate.

Lentiviral Vector In Gene Therapy Market Competitive Analysis

One of the key players in the competitive Lentiviral Vector in Gene Therapy market is Thermo Fisher Scientific. Thermo Fisher Scientific is a global biotechnology company that offers a wide range of products and services for the life sciences industry. The company has a strong presence in the gene therapy market, offering high-quality Lentiviral vectors for gene delivery. Thermo Fisher Scientific has a proven track record of innovation and expertise in the development of gene therapy products.

Another major player in the market is Vigene Biosciences, a leading provider of viral vector products and services for gene therapy applications. Vigene Biosciences has a strong focus on quality and innovation, which has helped the company to establish itself as a key player in the gene therapy market. Vigene Biosciences has experienced significant growth in recent years, driven by the increasing demand for Lentiviral vectors in gene therapy research and applications.

OriGene Technologies is also a prominent player in the Lentiviral Vector in Gene Therapy market, offering a wide range of Lentiviral vectors and other gene therapy products. OriGene Technologies has a strong presence in the market, backed by its extensive experience and expertise in gene therapy research and development. The company has witnessed substantial market growth and has been able to capture a significant market share in the gene therapy market.

In terms of sales revenue, companies like Thermo Fisher Scientific and Vigene Biosciences have reported strong financial performance in recent years, reflecting the growing demand for Lentiviral vectors in gene therapy applications. These companies have continued to invest in research and development to expand their product offerings and stay ahead of the competition in the gene therapy market.

Purchase this Report: https://www.reportprime.com/checkout?id=10093&price=3590

Contact Us: Name: Mahesh Patel Phone: +1 507 500 7209 Email: sales@reportprime.com

At ReportPrime.com, our vision is to revolutionize the market research industry by delivering unprecedented value to our clients through our audacious goal of providing unparalleled research quality, ethical practices, and affordability. We strive to empower businesses of all sizes with actionable, accurate, and unbiased insights that inform strategic decision-making, drive growth and innovation. We are committed to fostering a culture of excellence, integrity, and transparency, and to fostering lasting partnerships with our clients through affordability and dedicated client servicing.

This release was published on openPR.

Go here to read the rest:
Lentiviral Vector In Gene Therapy Market Forecasts, Market Trends and Impact Analysis (2024 - 2031) - openPR

Comments Closed|

Roche, Ascidian to develop gene therapies for neurological diseases – LabPulse

June 25th, 2024

Roche has announced a research collaboration and licensing agreement with biotech firm Ascidian Therapeutics to develop gene therapies for neurological diseases.

According to the terms of their agreement, Roche will pay Ascidian $42 million upfront for exclusive, target-specific rights to use Ascidian's RNA exon-editing technology to develop therapeutics for undisclosed neurological diseases, the firms said in a statement. Furthermore, Roche will pay Ascidian up to $1.8 billion in total as research, clinical, and commercial milestones are reached. Ascidian is also eligible to receive royalties on commercial sales worldwide for any therapies that are developed under the collaboration.

Under their arrangement, Ascidian will be responsible for conducting discovery and certain preclinical activities in collaboration with Roche, and Roche will be responsible for certain other preclinical activities, as well as further clinical development, manufacturing, and commercialization, Ascidian said. While Roche will have exclusive rights to the technology for the targeted diseases, Ascidian can pursue other disease targets outside of its agreement with Roche.

Boston-based Ascidian's exon-editing technology is designed to correct the RNA produced by damaged exons, the regions of DNA containing the blueprints to make proteins. Correcting the RNA produced by damaged exons greatly mitigates the risks associated with direct DNA editing and gene replacement, such as off-target edits, Ascidian said.

Original post:
Roche, Ascidian to develop gene therapies for neurological diseases - LabPulse

Comments Closed|

Medical Breakthroughs: Using genetic testing to improve treatment outcomes – KRGV

June 25th, 2024

A simple blood draw or saliva sample can identify opportunities for prevention, single out the best clinical trials, and improve treatment outcomes.

This type of genetic testing can cost hundreds of dollars, and is sometimes not covered by insurance.

We actually recognize that it's going to be the most cost-effective care as well, Stephen Gruber, chair of the Center for Precision Medicine at City of Hope, said.

City of Hope is one of the first cancer centers in the world to offer free genetic testing to every single patient, and possibly their immediate families.

Someone I recently spoke to was identified to have a genetic change that increased her risk for breast and ovarian cancer, and we got those results in just before she was about to start chemotherapy, City of Hope genetic counselor manager Bita Nehoray said. It actually changed things for her, and we were able to offer her a more appropriate and better line of therapy."

The panel tests 189 genes related to the risk of cancer and other inherited diseases.

It's been a tremendous game changer, as it relates to prevention in families, but also in really personalizing the most appropriate treatment plan, Nehoray said.

Taking part in the genetic testing is completely free to the patients. City of Hope will soon begin offering the inspire study testing nationwide in their locations in Los Angeles, Atlanta, Chicago, and Phoenix.

Watch the video above for the full story.

Read more from the original source:
Medical Breakthroughs: Using genetic testing to improve treatment outcomes - KRGV

Comments Closed|

Precision Diagnostics Market Size to Reach USD 270.31 Billion by 2033 – BioSpace

June 25th, 2024

According to the latest report the global precision diagnostics market size was USD 76.19 billion in 2023, calculated at USD 86.48 billion in 2024, and is expected to reach around USD 270.31 billion by 2033, expanding at a CAGR of 13.5% from 2024 to 2033. North America dominated the market with the largest revenue share of 49.19% in 2023.

Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/8556

The precision diagnostics market refers to the segment of the healthcare industry that focuses on the development and application of diagnostic tests and tools designed to accurately detect and characterize diseases at a molecular or genetic level. Precision diagnostics aim to provide tailored and precise information that can guide personalized treatment decisions, improve patient outcomes, and reduce healthcare costs. These diagnostics encompass a wide range of technologies including genetic testing, molecular diagnostics, companion diagnostics, next-generation sequencing (NGS), biomarker analysis, and advanced imaging techniques.

Growth factors

Precision Diagnostics Market Key Takeaways

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8556

Market dynamics

Driver

Rising demand for early detection of diseases

Precision diagnostics provide the ability to detect diseases at an early stage, improving the chances of successful treatment and reducing healthcare costs by avoiding late-stage interventions. Focused on offering Multiple countries with the support of government fundings and private investments are focusing on early detection of diseases, this acts as a major driver for the market. The expanding field of precision medicine, which relies heavily on precision diagnostics for patient stratification and treatment selection, propels the demand for advanced diagnostic tools.

Restraint

Complexity in data interpretation

The high cost of advanced diagnostic tests and technologies can limit their accessibility and affordability, particularly in low- and middle-income countries. The complexity of interpreting genetic and molecular data requires specialized expertise and infrastructure, which can be a barrier to widespread adoption in clinical settings. Stringent regulatory requirements and varying regulations across different regions can pose challenges for the approval and commercialization of precision diagnostics.

Opportunity

Growing healthcare infrastructure and increasing investments in emerging markets present significant opportunities for the expansion of precision diagnostics in regions such as Asia-Pacific and Latin America. The integration of precision diagnostics with digital health technologies, such as telemedicine and health informatics, can improve patient management and facilitate remote monitoring and diagnosis. Thereby, the integration of digital health is observed to act as an opportunity for the market.

Personalized your customization here@

https://www.novaoneadvisor.com/report/customization/8556

U.S. Precision Diagnostics Market Size and Growth 2024 to 2033

The U.S. precision diagnostics market size was estimated at USD 26.23 billion in 2023 and is projected to hit around USD 97.19 billion by 2033, growing at a CAGR of 12.73% during the forecast period from 2024 to 2033.

North America dominated the precision diagnostics market with the largest revenue share of 49.19% in 2023, mainly the U.S., which is known for its advanced healthcare infrastructure and robust biotechnology research sectors. Continuous investments and developments in these areas have led to innovations in personalized diagnostics technologies, making them more efficient and reliable. Government initiatives in North America aimed at improving healthcare quality and accessibility, along with funding for research and development in the field of diagnostics, have significantly contributed to the market growth.

U.S. Precision Diagnostics Market Trends

The precision diagnostics market in the U.S. is expected to grow at the fastest CAGR over the forecast period, driven by advancements in genomic medicine, increased awareness of personalized healthcare, the integration ofartificial intelligence (AI)in diagnostic processes, and rising demand for early and more accurate disease detection. Precision diagnostics, which includesgenetic testing, molecular diagnostics, and companion diagnostics, among others, focus on identifying unique genetic and biomolecular characteristics to guide more tailored treatment strategies.

The U.S. government and private sectors have supported research and initiatives related toprecision medicineand diagnostics. Programs such as the Precision Medicine Initiative (PMI) aim to revolutionize how diseases are treated and prevented by considering individual differences in peoples genes, environments, and lifestyles.

Europe Precision Diagnostics Market Trends

The precision diagnostics market in Europe was identified as a lucrative region in this industry. The Europe market is experiencing significant growth. This growth can be attributed to advancements in technologies, increasing healthcare expenditures, the rising prevalence of chronic diseases, and the growing emphasis onpersonalized medicine. The regulatory environment in Europe is also adapting to the advancements in precision diagnostics, with efforts to streamline approval processes for new diagnostic technologies. In addition, collaborations between diagnostic companies, research institutions, and healthcare providers are fostering innovation and accelerating the development of new diagnostic solutions.

The UK precision diagnostics market held a significant share in 2023.There is a growing emphasis on personalized healthcare in the UK. Treatments and diagnostics are tailored to individual genetic profiles, improving patient outcomes and treatment efficacy. The UK government and healthcare system are supportive of precision medicine initiatives. For instance, the NHS has launched the 100,000 Genomes Project and continues to invest in genomic medicine, creating a conducive environment for the growth of precision diagnostics.

The precision diagnostics market in France is expected to grow at a remarkable CAGR over the forecast period,driven by the increasing incidence of chronic diseases, such as cancer, cardiovascular diseases, and diabetes, which has heightened the demand for early and accurate diagnostic solutions. This need is critical in managing these conditions effectively, leading to a push for advancements in diagnostic technologies. France has an aging population. This demographic trend results in a higher prevalence of various diseases, necessitating the development and implementation of advanced diagnostic tools to cater to the growing healthcare needs of this segment of the population.

The Germany precision diagnostics market is anticipated to grow at a significant CAGR over the forecast period.The Germany market is characterized by a strong focus on innovation and quality, reflecting the country's leading position in healthcare and medical technology. With a robust healthcare system and a high level of spending on healthcare relative to GDP, Germany presents a productive ground for the growth and adoption of personalized diagnostics technologies. Regulatory frameworks in Germany are designed to ensure patient safety while promoting technological advancements. The Federal Institute for Drugs and Medical Devices (BfArM) and the Paul-Ehrlich-Institute (PEI) are key regulatory bodies that oversee the approval and market surveillance of diagnostic products. These agencies work to balance innovation with strict safety standards, ensuring that new diagnostic technologies entering the market are effective and reliable.

Asia Pacific Precision Diagnostics Market Trends

The precision diagnostics market in Asia Pacific is anticipated to grow at the fastest CAGR of 12.8% over the forecast period. The increasing prevalence of chronic diseases, such as cancer and diabetes, in this region drives the demand for advanced diagnostic methods that can provide personalized treatment options. The growing awareness and acceptance of precision diagnostics among healthcare professionals and patients contribute to this rapid growth. Improvements in healthcare infrastructure, mainly in emerging economies such as China and India, along with government initiatives aimed at incorporating advanced healthcare technologies, further bolster the market expansion. The rising investment in healthcare research and development, coupled with collaborations between public and private sectors in the field of precision medicine, are also significant contributors.

The China precision diagnostics market is expected to grow at a rapid CAGR over the forecast period. China has seen rapid advancements in healthcare infrastructure and technology. The government and private sector have invested robustly in healthcare innovation, particularly in precision medicine, which includesgenomicsand personalized healthcare solutions. This focus aligns with the global trend toward more personalized and precise medical interventions based on individual genetic and molecular profiles.

The precision diagnostics market in Japan has one of the highest proportions of elderly citizens in the world. This demographic trend increases the demand for healthcare services, including precision diagnostics, as older populations typically have higher incidences of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders. The Japanese government actively promotes healthcare innovation through funding, research programs, and regulatory reforms designed to facilitate the development and adoption of new medical technologies. Initiatives such as the Japan Health Sciences Foundation and the Japan Agency for Medical Research and Development (AMED) support research in precision medicine and diagnostics.

Middle East & Africa Precision Diagnostics Market Trends

The precision diagnostics market in Middle East & Africa is expected to grow at a exponential CAGR over the forecast period. Countries across the MEA are significantly investing in healthcare infrastructure and services. This includes the development of state-of-the-art medical facilities and hospitals, which are essential for implementing advanced diagnostic technologies. The MEA region is witnessing a surge in chronic diseases such as diabetes, cardiovascular diseases, and cancer. Precision diagnostics play a crucial role in the early detection and management of these conditions, making them important in regional healthcare.

The Saudi Arabia precision diagnostics market is expected to grow at the fastest CAGR over the forecast period. The Saudi Arabian government has been actively investing in healthcare infrastructure and digital health technologies as part of its Vision 2030 program. This includes initiatives aimed at enhancing the precision diagnostics sector, such as funding for research and development and the establishment of state-of-the-art medical facilities equipped with the latest diagnostic technologies. There has been an increase in the prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer in Saudi Arabia. Precision diagnostics play a crucial role in the early detection and management of these conditions, driving demand for advanced diagnostic services.

The precision diagnostics market in Kuwait is anticipated to grow at a significant CAGR over the forecast period. Kuwait is witnessing a substantial adoption of digital health technologies. The use of artificial intelligence (AI) andmachine learningfor data analysis in healthcare is becoming more common. These technologies are improving the accuracy and efficiency of disease diagnosis and treatment plans, thus boosting the capabilities of precision diagnostics. There's a focus on ensuring that healthcare professionals in Kuwait are up-to-date with the latest diagnostic technologies and techniques. Education and training programs are critical for equipping the healthcare workforce with the necessary skills to utilize precision diagnostics tools effectively.

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8556

Precision Diagnostics Market By Type Insights

Based on type, the genetic tests segment led the market with the largest revenue share of 45.15% in 2023. The dominance of genetic tests in the market can be attributed to technological advancements, a better understanding of genetic disorders, the rise of personalized medicine, an increase in chronic diseases and cancer, consumer interest, and a supportive regulatory environment. Furthermore, the sector has witnessed significant investments and collaborations between diagnostic companies, pharmaceutical companies, and academic institutions. These partnerships aim to develop new genetic tests and integrate them into clinical practice, further driving market growth. For instance, in January 2024, DNAnexus, Inc. and TMA Precision Health announced a collaboration to enhance diagnostic processes and treatment alternatives for rare diseases. This partnership is focused on developing more accurate and efficient diagnostic tools that can lead to better personalized treatment plans for individuals suffering from rare conditions.

The Direct-to-Consumer Tests (DTC)segment is anticipated to register at the fastest CAGR from 2024 to 2033. There's a growing awareness among consumers about the importance of early disease detection and personalized health information. DTC tests provide a convenient way for individuals to access health information directly without necessarily going through a healthcare provider. Advancements in genomic sequencing technologies and bioinformatics have made it easier and more cost-effective to offer these tests directly to consumers. This has led to an increase in the variety and accuracy of tests available, from genetic predisposition to certain conditions to personalized nutrition and fitness advice. Regulatory bodies in some regions have started providing clearer frameworks and guidelines for DTC genetic testing, which has helped companies navigate the approval process more efficiently and bring their products to market.

Precision Diagnostics Market By Application Insights

Based on application, the oncology segment led the market with the largest revenue share of 25.7%in 2023. This is primarily due to the increasing prevalence of cancer worldwide and the need for early detection and monitoring of this disease. According to the American Cancer Society, approximately 1.96 million new cases of cancer were diagnosed in 2023. This high prevalence demands more personalized and accurate diagnostic methods to identify specific cancer types and their genetic makeup, facilitating targeted treatment approaches. In addition, government investment in this segment is expected to boost the market in the forecast years. For instance, in the U.S., the National Cancer Institute (NCI) received USD 7.8 billion from the government and a USD 500 million increase from the Fiscal Year 2023 budget to support personalized medicine.

The genetic diseases application segment is expected to grow at the fastest CAGR during the forecast period. The rising incidence of genetic disorders worldwide is driving the demand for personalized diagnostic solutions. Conditions such as cystic fibrosis, sickle cell anemia, and various forms of cancer have genetic roots, necessitating advanced diagnostics for early detection and management. The advent of next-generation sequencing (NGS) and other high-throughput technologies has revolutionized genetic testing. These advancements have made it possible to analyze and interpret large volumes of genetic data quickly and cost-effectively, thereby accelerating the growth of precision diagnostics in identifying genetic diseases.

Precision Diagnostics Market By End-use Insights

Based on end-use, the clinical laboratories segment led the market with the largest revenue share of 48.11% in 2023.Clinical laboratories play a key role in the market, primarily due to their extensive use of advanced diagnostic technologies for accurate disease detection and monitoring. Precision diagnostics often requires the interpretation of complex data, such as genetic mutations or biomarker levels. Clinical laboratories have the expertise and personnel, such as pathologists and geneticists, to interpret these results accurately, making them a crucial end-use segment. Furthermore,clinical laboratories offer a wide range of diagnostic services, from routine blood tests to complex genetic testing. This flexibility attracts a broad patient base, further driving the demand for personalized diagnostics.

The hospital segment is anticipated to grow at a significant CAGR during the forecast period. Hospitals are adopting precision diagnostic technologies, driven by the need for more accurate and individualized patient care. This adoption is facilitated by advancements in diagnostic technologies, such as next-generation sequencing (NGS), PCR (polymerase chain reaction), and liquid biopsy, which are becoming more accessible and integrated into hospital settings. In addition, rising investment and collaborations by private players in the market are expected to support market growth. For instance, in January 2024, Qlucore Insights, a software development company for precision diagnostics, signed an agreement with Sahlgrenska University Hospital in Sweden. Through the agreement, the hospital will use the Qlucore Insights software to improve the diagnosis of acute lymphoblastic leukemia in children.

Related report:

Diagnostic Testing Market : https://www.biospace.com/article/releases/diagnostic-testing-market-size-to-reach-usd-449-78-billion-by-2033/

Genomics Market: https://www.biospace.com/article/releases/genomics-market-size-to-hit-usd-157-47-billion-by-2033/

Oncology Market : https://www.biospace.com/article/releases/laxman-dige-precedenceresearch-com/

Biotechnology Market : https://www.biospace.com/article/biotechnology-market-size-to-reach-usd-5-68-trillion-by-2033/

Next Generation Sequencing Market : https://www.biospace.com/article/next-generation-sequencing-market-size-to-reach-usd-66-04-bn-by-2033/

Single Cell Genome Sequencing Market : https://www.biospace.com/article/releases/single-cell-genome-sequencing-market-size-to-hit-usd-12-79-bn-by-2032/

DNA Diagnostics Market: https://www.biospace.com/article/releases/dna-diagnostics-market-size-to-hit-usd-16-05-billion-by-2033/

Liquid Biopsy Market : https://www.biospace.com/article/releases/liquid-biopsy-industry-is-rising-rapidly-up-to-usd-32-54-bn-by-2033/

Point Of Care Diagnostics Market : https://www.biospace.com/article/point-of-care-diagnostics-market-size-to-increase-usd-80-75-bn-by-2033/

Clinical Trials Market : https://www.biospace.com/article/releases/clinical-trials-market-size-to-increase-usd-153-59-billion-by-2033/

Breast Cancer Diagnostics Market: https://www.biospace.com/article/breast-cancer-diagnostics-market-size-share-and-growth-report-2033/

U.S. Oncology Molecular Diagnostics Market: https://www.biospace.com/article/u-s-oncology-molecular-diagnostics-market-size-to-reach-usd-2-74-bn-by-2033/

U.S. In Vitro Diagnostics Market: https://www.biospace.com/article/releases/u-s-in-vitro-diagnostics-market-size-to-hit-usd-45-78-bn-by-2033/

U.S. Tissue Diagnostics Market : https://www.biospace.com/article/releases/u-s-tissue-diagnostics-market-size-to-hit-usd-3-61-billion-by-2033/

U.S. Clinical Trials Market: https://www.biospace.com/article/releases/u-s-clinical-trials-market-size-industry-analysis-report-2033/

U.S. Biotechnology Market : https://www.biospace.com/article/releases/u-s-biotechnology-market-size-to-increase-usd-1-79-trillion-by-2033/

Antibiotics Market: https://www.biospace.com/article/releases/antibiotics-market-size-to-reach-usd-85-80-billion-by-2033/

U.S. Cancer Biopsy Market : https://www.biospace.com/article/releases/u-s-cancer-biopsy-market-size-to-surpass-usd-29-34-bn-by-2033/

U.S. Next Generation Sequencing Market: https://www.biospace.com/article/releases/u-s-next-generation-sequencing-market-size-to-worth-usd-25-71-bn-by-2033/

U.S. Clinical Trial Imaging Market: https://www.biospace.com/article/releases/u-s-clinical-trial-imaging-market-size-to-hit-usd-875-93-mn-by-2033/

Synthetic Biology Market : https://www.biospace.com/article/synthetic-biology-industry-is-rising-rapidly-up-to-usd-80-17-bn-by-2033/

Biosimilars Market: https://www.biospace.com/article/releases/biosimilars-market-size-poised-to-hit-usd-150-26-billion-by-2033/

Immuno-Oncology (IO) Market : https://www.biospace.com/article/immuno-oncology-io-market-size-to-hit-usd-284-29-billion-by-2033/

Breast Cancer Drugs Market: https://www.biospace.com/article/releases/breast-cancer-drugs-market-size-to-surpass-usd-78-61-bn-by-2033/

Precision Diagnostics Market Recent Developments

Key Precision Diagnostics Company Insights

The market players operating in the global market are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

The following are the leading companies in the precision diagnostics market. These companies collectively hold the largest market share and dictate industry trends.

Precision Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Precision Diagnostics market.

By Type

By Application

By End-use

By Region

Immediate Delivery Available | Buy This Premium Research

https://www.novaoneadvisor.com/report/checkout/8556

Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @

https://www.novaoneadvisor.com/report/checkout/8556

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818

Email: sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com/

See the rest here:
Precision Diagnostics Market Size to Reach USD 270.31 Billion by 2033 - BioSpace

Comments Closed|

Color Health uses OpenAI to develop cancer screening copilot for doctors – Healthcare IT News

June 25th, 2024

Color Health, a genetic testing company, is using OpenAI's newest, less expensive, large language model to equip doctors with pretreatment workup expertise that could speed up prior authorization requests for cancer screening diagnostics and get patients into treatment faster.

The company has also partnered with the University of California San Francisco to study how the cancer copilot tool performs in surfacing early warning signs, seemingly incongruous red flags and other pertinent details that may be deeply dispersed throughout electronic health records and other patient information.

WHY IT MATTERS

While decision factors for different types of cancers vary, a trial of the technology helped providers analyze patient records in five minutes, according to the company.

"Primary care doctors dont tend to either have the time or sometimes even the expertise, to risk-adjust peoples screening guidelines," Othman Laraki, cofounder and chief executive of Color Health, said in aWall Street JournalreportMonday.

The UCSF Helen Diller Family Comprehensive Cancer Center is testing Colors copilot for cancer pretreatment diagnostic work-ups by comparing it to retrospective analyses of cancer patient charts.

Though that study is in the early stages, according to a Color Spokesperson, if AI can ultimately reduce wait times for cancer treatment by connecting the dots, that's a patient care win.

In Color'sannouncementMonday, Laraki said the company designed the tool to address the supply gap in oncology expertise to decide on a pre-treatment workup for a patient with a confirmed malignancy.

The goal is to offer primary care doctors and other clinicians an AI service that can determine what tests are needed to inform the patient's cancer treatment, without waiting for the patient to see an oncologist before pretreatment diagnostics are ordered and the prior authorization process is initiated, he explained.

"That way, by the time the patient meets her oncologist for the first time, she has a much higher chance of being ready to initiate treatment and, we hope, save weeks of precious time."

Laraki also stressed the clinician's role in decision-making when using the tool.

"One of the most important design decisions behind our work is that the tools were built from the ground up to be based on a human-in-the-loop model," he said.

The company said it will share the results of the first use case tested which focuses on automating the analysis of a persons background risk factors and then applying the guidelines that adjust their screening plan first with individuals in its cancer program, and then give primary care doctors a chance to review the information.

Color estimated that physicians using the cancer copilot will have supported more than 200,000 patient cases in generating AI personalized care plans by the end of the year.

THE LARGER TREND

Before focusing on tools to help doctors improve cancer patient outcomes, Color launched its model of patient-initiated proactive testing in 2015. The tests focused on genes known to increase an individuals cancer risk, such as BRCA1 and BRCA2 for breast, ovarian cancer and pancreatic.

Within a few years, theunicorn, along with 23andMe and other companies, shattered patient barriers to cancer screening not previously possible by offering low-cost, over-the-counter home test kits that could illuminate key genetic risk factors.

Using AI for a new decision support service that empowers PCPs to get their patients with cancer into treatment faster is a budding area in healthcare AI where automating physician note-taking and reducing clinical administrative burden have made up the majority of mainstream LLM use cases.

However, applying machine learning to health data is amajor opportunityto enhance health outcomes for individuals and populations.

AI could be instrumental in disease management, said Xin Wang, assistant professor in the University at Albany department of epidemiology and biostatistics.

"By analyzing patient data over time, AI algorithms can predict individual patient risks, suggest personalized treatment plans and even alert healthcare providers to early signs of complications," he toldHealthcare IT Newsin January.

"This proactive approach can lead to earlier interventions, better disease management and, ultimately, improved health outcomes."

ON THE RECORD

"We see a perfect fit for AI technology, for language models," Brad Lightcap, OpenAIs chief operating officer, said in theWSJstory. "They can give clinicians more tools to understand medical records, to understand data, to understand labs and diagnostics."

Andrea Fox is senior editor of Healthcare IT News. Email:afox@himss.org Healthcare IT News is a HIMSS Media publication.

The HIMSS AI in Healthcare Forum is scheduled to take place September 5-6 in Boston.Learn more and register.

Continue reading here:
Color Health uses OpenAI to develop cancer screening copilot for doctors - Healthcare IT News

Comments Closed|

Bone marrow transplantation reduces FGF-23 levels and restores bone formation in myelodysplastic neoplasms … – Nature.com

June 25th, 2024

Myelodysplastic neoplasms (MDS) are hematopoietic stem cell disorders characterized by ineffective hematopoiesis and dysplastic cells in the bone marrow (BM) [1]. In addition, patients with MDS display an increased susceptibility to osteoporosis [2]. Evidence points towards dysregulation in the BM niche that concurrently impairs bone turnover and hematopoiesis. We identified fibroblast growth factor (FGF)-23 as a critical regulator of bone mineralization and erythropoiesis. FGF-23 serum levels were higher in both patients and mice with MDS, and its neutralization resulted in improved erythropoiesis and bone mineralization in NUP98/HOXD13 (NHD13) mice [3]. FGF-23 is mainly produced by osteoblasts/osteocytes [4] and exerts phosphaturic effects leading to poor bone mineralization [5]. However, in NHD13 mice, intact FGF-23 (iFGF-23) and C-terminal FGF-23 (cFGF-23; produced by the cleavage of the intact form) protein levels were unchanged in the bone tissue, but erythroid progenitors secreted more FGF-23 compared to littermate wild-type (WT) controls (Fig.S1A, B).

Here, we tested the hypothesis that erythroid precursors contribute to increased FGF-23 production/cleavage in MDS as a cause for impaired erythropoiesis and bone mineralization. To that end, we used BM transplantation as a first approach to substitute myelodysplastic erythroblasts with healthy ones in NHD13 mice. Four months after the BM transplantation, all mice that received the NHD13 BM showed MDS-like symptoms. In WT recipients, a reduction in hemoglobin levels [32%; p<0.001], platelets [20%; p<0.05], and lymphocytes [71%; p<0.001], but not in neutrophils or monocytes was observed compared to WT controls (transplanted with WT BM), showing a similar MDS status as NHD13 controls. In turn, NHD13 mice transplanted with WT BM did not develop MDS during the observation period. Compared to NHD13 controls, blood count reached normal levels [hemoglobin: +22%; p<0.001; platelets: +26%; p<0.05; lymphocytes: +6.5-fold; p<0.001; neutrophils: +2-fold; p<0.001] (Fig.1AE). This confirms that the MDS blood phenotype is transferable via hematopoietic cells. In line with NHD13 mice only showing increased cFGF-23 levels, but normal serum levels of iFGF-23 [3], the transplantation of WT or NHD13 BM into either WT or NHD13 recipient mice did not alter iFGF-23 (Fig.1F). In contrast, cFGF-23 was increased in all recipients of NHD13 BM [WT: +3.5-fold; p<0.05; NHD13: +2.1-fold; p<0.01] compared to the corresponding mice with WT BM (Fig.1G). Because of the transferable FGF-23 status, we hypothesized that WT mice receiving NHD13 BM would exhibit a bone phenotype mimicking the NHD13 controls. That was the case regarding the increased bone formation parameters usually observed in NHD13 mice. Similar to NHD13 mice, WT mice receiving NHD13 BM showed an increased number of osteoblasts [+95%; p<0.001] concomitant with elevated levels of the bone formation marker procollagen type I N-propeptide [+45%; p<0.05] and an increased bone formation rate [+87%; p<0.01] (Fig.1HJ). Also, the osteoid surface per bone surface tended to be increased [+44%; p=0.056] (Fig.1K). Importantly, transplanting WT BM to NHD13 mice normalized their bone formation parameters (Fig.1HK), indicating that hematopoietic cell signals control bone formation in NHD13 mice.

Eigth-week-old male wild-type (WT) and NUP98/HOXD13 (NHD13) mice were lethally irradiated one day before 2106 total bone marrow cells of age-matched WT (WT BM) or NHD13 (NHD13 BM) donor mice were transplanted by intravenous injection. After 16 weeks all mice were sacrificed and analyzed. The blood count, (A) hemoglobin levels (WT BMWT: n=9; NHD13 BMWT: n=9; WT BMNHD13: n=14; NHD13 BMNHD13: n=8), (B) platelet number (WT BMWT: n=8; NHD13 BMWT: n=8; WT BMNHD13: n=14; NHD13 BMNHD13: n=7) as well as the number of (C) neutrophils, (D) lymphocytes (WT BMWT: n=8; NHD13 BMWT: n=8; WT BMNHD13: n=14; NHD13 BMNHD13: n=8), and (E) monocytes (WT BMWT: n=8; NHD13 BMWT: n=7; WT BMNHD13: n=15; NHD13 BMNHD13: n=7) were received using the Sysmex XN-100 (Sysmex, Norderstedt, Germany). After collecting the serum, (F) the intact (WT BMWT: n=9; NHD13 BMWT: n=8; WT BMNHD13: n=14; NHD13 BMNHD13: n=9) as well as (G) C-terminal fibroblast growth factor (FGF)-23 (WT BMWT: n=8; NHD13 BMWT: n=6; WT BMNHD13: n=13; NHD13 BMNHD13: n=8) were measured by ELISA. (H) The osteoblasts per bone perimeter were evaluated in TRAP-stained vertebral bone slices (WT BMWT: n=9; NHD13 BMWT: n=9; WT BMNHD13: n=14; NHD13 BMNHD13: n=9) and (I) the osteoblast activity was assessed by procollagen type I N-propeptide (P1NP) using ELISA (WT BMWT: n=8; NHD13 BMWT: n=9; WT BMNHD13: n=14; NHD13 BMNHD13: n=9). J To determine the bone formation rate in vertebrae, mice received intraperitoneal calcein injection 5 and 2 days before sacrifice for the double labeling analysis (WT BMWT: n=9; NHD13 BMWT: n=6; WT BMNHD13: n=13; NHD13 BMNHD13: n=6). K Embedded vertebrae were stained with von Kossa/van Gieson to determine the osteoid surface per bone surface (WT BMWT: n=6; NHD13 BMWT: n=8; WT BMNHD13: n=14; NHD13 BMNHD13: n=5). Data are shown as meanSD of five independent experiments. Statistical analysis was performed by two-sided Students t test. *p<0.05; **p<0.01; ***p<0.001.

To address whether stem cell transplantation (SCT) leads to similar changes in FGF-23 in patients with MDS, we employed samples from the BoHemE study, in which we previously confirmed the high plasma iFGF-23 and cFGF-23 levels in patients with MDS [3]. Within this cohort, we identified 10 patients with MDS (3 women, 7 men; median age: 64 years; without renal disease) who had undergone SCT. We analyzed their hematological and bone-specific parameters before (range: 16 months) and after SCT (range: 511 months). SCT led to a higher number of red blood cells in 9/10 patients, neutrophils in 9/10 patients, and lymphocytes in 6/10 patients with normal monocyte counts. Platelet counts were below the reference range in 8/10 patients and higher in 1/10 patients before SCT, but only 4 patients had persistent thrombocytopenia after SCT (Figs.2A, S2AD). Before SCT, 5 patients showed elevated cFGF-23 plasma levels, which were normalized after SCT (Fig.2B). Elevated iFGF-23 levels were observed in 2 patients before SCT, with levels decreasing post-SCT. However, after SCT, iFGF-23 levels slightly increased in all patients with normal baseline levels (Fig.2C). Additionally, 7/10 patients had reduced osteocalcin levels (bone formation) before SCT, though this did not result in abnormal bone mineral density (BMD) (Fig.2D, TableS1). Given that bone mineralization is impaired in MDS [3], we also analyzed albumin-adjusted calcium, phosphate, and bone-specific alkaline phosphatase (BSAP). Calcium levels were reduced in 2/5 patients with elevated cFGF-23 and normalized after SCT (Fig.2E). All patients with normal cFGF-23 had calcium levels within the reference range, with only one showing reduced levels of phosphate, which were corrected by the SCT. Whereas 3/5 patients with high cFGF-23 had mild to moderate hypophosphatemia before SCT, only one remained hypophosphatemic after SCT (Fig.2F). In line with the increase of serum phosphate, BSAP levels, the major regulator of bone mineralization, also increased after SCT with high cFGF-23 (determined in 3/5 patients only, Fig.S2E). In addition, we analyzed 10 BM plasma samples regarding cFGF-23 and iFGF-23 levels in a separate set of patients with MDS (4 women, 6 men; median age: 57 years; TableS2). Since the samples were collected relatively shortly after SCT (range: 28 months), it is not surprising that the number of red blood cells was equal or decreased after SCT in 4/9 patients (data from one patient are not evaluable) compared to the basal levels (Fig.2G). In line with our previous observations, before SCT 5/10 patients had elevated cFGF-23 levels, which normalized after SCT. In patients with normal baseline cFGF-23, levels were either slightly increased (1/5 patients) or decreased (2/5) after SCT (Fig.2H). Before SCT, all patients had normal iFGF-23 levels. The SCT led to an increase in 6/10 patients and a decrease in 4/10 patients independently of the basal iFGF-23 levels (Fig.2I). Overall, the regulation of cFGF-23 in blood and BM plasma samples from patients with MDS after SCT suggests that BM cells are a source for cFGF-23 in MDS. This is supported by the transplantation of NHD13 BM cells, which causes the increase of cFGF-23 levels leading to impaired erythropoiesis and bone mineralization. Only erythroid precursors of NHD13 mice show a high Fgf23 expression, but myeloid cells and megakaryocytes do not (Fig.S1C, D). The question remains why and how cFGF-23 levels are increased in MDS. The expression of Galnt3 and Fam20c, which stabilize or mark FGF-23 for cleavage [6, 7], was normal in NHD13 erythroid precursors (Fig.S1E, F), indicating that these cells do not directly contribute to the increased cleavage of erythroid-derived FGF-23. Therefore, other signals or cells within the bone microenvironment or beyond may participate in this regulation. In line with this, it has been shown that FGF-23 production/cleavage can be triggered by erythropoietin, iron deficiency, anemia, and inflammation [8,9,10], factors that also play a role in MDS [11, 12]. While iron serum levels are unchanged in NHD13 mice, erythropoietin is upregulated. Since erythropoietin can affect FGF-23 production/cleavage in WT erythroid cells [8], this may be a possible regulator also in NHD13 mice. The whole inflammatory status of NHD13 mice has not been described yet, suggesting that inflammation and/or anemia might be drivers of cFGF-23 in NHD13 mice as well. The production of cFGF-23 is increased by inflammation, inhibits hepcidin induction in the liver, and increases iron bioavailability independent of the functions of iFGF-23 [10]. This scenario may hold true for MDS as it is also characterized by inflammation (and anemia) and may require high levels of cFGF-23 to provide enough iron for erythropoiesis. In our human cohorts, not all patients with MDS showed elevated cFGF-23 levels, and not all patients with elevated cFGF-23 showed dysregulations of iron or inflammation (TableS1). All patients with elevated cFGF-23 however did have anemia. MDS is a heterogeneous group of disorders. As NHD13 mice mimic a severe form of MDS with a high percentage of blasts in the bone marrow and a high propensity to transformation towards acute leukemia [13], we included patients with intermediate to very high-risk MDS in our cohorts and indicated their mutations. Analyzing the mutational landscape in patients with MDS might further allow assumptions on the underlying mechanisms leading to increased cFGF-23 levels. Mutations like TET2, DNMT3A, ASXL1, RUNX1, SF3B1, and SRSF2 are linked to increased responses to inflammatory stimuli [12, 14], and Tet2 or Dnmt3a deficiency causes bone loss in mice due to increased osteoclastogenesis [15]. In our blood plasma cohort, 4/5 patients with elevated cFGF-23 carried a mutation in at least one of these genes. However, 2/5 patients with normal cFGF-23 also had these mutations, but they received the MDS diagnosis a month earlier only. It is conceivable that the cFGF-23 levels increase after some time. Future research is needed to determine whether any of these mutations contribute to high cFGF-23 levels. In summary, we show that the high serum cFGF-23 levels in MDS originate from the BM and that BM transplantation/SCT can reduce cFGF-23 levels and its associated negative effects on erythropoiesis and bone mineralization. Future studies need to validate these findings in humans and address why cFGF-23 levels are increased in MDS.

The hematological and plasma parameters of patients with MDS were analyzed before and after allogeneic stem cell transplantation (SCT) in blood (AF) and bone marrow samples (GI). A, G The number of red blood cells was determined by the Sysmex XN-100 (Sysmex, Norderstedt, Germany). B, H C-terminal fibroblast growth factor (FGF)-23, (C, I) intact FGF-23, as well as (D) osteocalcin, were determined in plasma samples and in serum (E) albumin-adjusted calcium levels, as well as (F) phosphate levels, were measured by ELISA. n=10 except (G) n=9. The grey boxes in the graphs mark the reference range of healthy individuals. In all graphs, each dot represents a patient with MDS, and the values from the same patient are connected by a line (normal C-terminal FGF-23 before SCT, n=5) or dotted line (high C-terminal FGF-23 before SCT, n=5).

Read more from the original source:
Bone marrow transplantation reduces FGF-23 levels and restores bone formation in myelodysplastic neoplasms ... - Nature.com

Comments Closed|

Allogeneic HSCT for Myelofibrosis: What to Know as More Patients Receive Treatment – Physician’s Weekly

June 25th, 2024

Photo Credit: Wildpixel

Authors of a recent review provide updates on stem cell transplants for myelofibrosis, with an emphasis on managing graft versus host disease and relapse.

Due to new transplant approaches, allogeneic hematopoietic stem cell transplant (HSCT) is now perceived as a safer therapeutic option in patients with myelofibrosis, even among older patients. Authors of a review published in the American Journal of Hematology emphasized the crucial role of early consideration and implementation of HSCT in improving clinical outcomes in this patient population.

Despite the approval of new therapies and various other exciting non-transplant treatments in development, allogeneic HSCT remains at present the only curative therapy for patients with myelofibrosis, wrote coauthors Haris Ali, MD, and Andrea Bacigalupo, MD.

The challenges associated with treating myelofibrosis include transplant-related mortality and the risk for relapse after HSCT. The authors aimed to provide a comprehensive review of current clinical data, new transplant platforms, and clinical updates, which can enhance patient outcomes.

The number of patients undergoing an allogeneic HSCT annually is steadily increasing, Dr. Ali and Dr. Bacigalupo wrote. This reflects the fact that HSCT has become safer with the reduction in non-relapse mortality over the years, making the choice of an HSCT more attractive among hematologists caring for [patients with myeloproliferative neoplasms].

Prior to HSCT, clinicians should conduct an in-depth assessment of organ functions, including cardiac, pulmonary, hepatic, and renal functions, as established by their institutions predefined criteria. This evaluation ensures that patients can withstand the possible physiological stresses of the transplant process, such as toxicity of the conditioning regimen, increased risk of infection, graft versus host disease (GVHD), and cytopenia. Patients should also undergo a detailed psychosocial assessment, which is an integral component of this process.

Following a thorough physical examination, we need to assess whether the patients disease justifies the risk from an allogeneic HSCT. Several prognostic scoring systems have been developed over the past years to identify patients who are likely to progress and are therefore at higher risk of morbidity and mortality, the authors explained.

The dynamic international prognostic scoring system is the most widely used prognostic tool for patients with myelofibrosis. Clinicians should account for patient age, as there are limited outcomes data regarding HSCT in patients with myelofibrosis who are aged 70 years or older.

The review offered information about approaches to managing splenomegaly and pretransplant treatment, recommended conditioning regimens, post-transplant outcome prediction models, recommendations for sourcing stem cells (eg, bone marrow, peripheral blood, cord blood), and criteria for selecting stem cell donors.

The authors provided protocol recommendations for preventing GVHD, managing patients with blast and accelerated phase myelofibrosis, and monitoring for disease markers. They also recommended monitoring driver mutations and early clinical intervention with cellular therapy to treat relapse. They also provided guidance for cases of hematologic reconstitution and graft failure.

The treatment is different according to the degree of donor chimerism: in patients who show mixed donor or only host-derived cells, the graft has failed completely, and the only solution is an early second transplant. On the other hand, if complete donor chimerism is present, then a boost of CD34 positive cells from the same donor, without conditioning regimen, can rescue over 70% of patients, Dr. Ali and Dr. Bacigalupo explained.

Myelofibrosis is a nuanced disease that often bears a significant transfusion burden and an unfavorable marrow environment, and early selection of patients for HSCT is critical to enhancing transplant outcomes.

HSCT in myelofibrosis is becoming safer due to new transplant strategies and is even offered in older patients. Early consideration of HSCT in patients with myelofibrosis is the key to the success of the transplant, Dr. Ali and Dr. Bacigalupo concluded.

Read more here:
Allogeneic HSCT for Myelofibrosis: What to Know as More Patients Receive Treatment - Physician's Weekly

Comments Closed|

Life After Sickle Cell: A Seven-Year-Old Was Cured Of The Disease Thanks To Her Younger Sister – Essence

June 25th, 2024

Today is World Sickle Cell Disease Day. The international awareness day is observed annually to increase public knowledge and an understanding of sickle cell disease and the challenges experienced by patients, their families, and caregivers. According to the CDC, Sickle cell disease (SCD) affects about 100,000 people in the United States; more than 90% are non-Hispanic Black or African Americans. The estimated life expectancy of those with SCD in the United States is more than 20 years shorter than the average expected. Sickle cell disease is an inherited blood disorder that affects red blood cells. People with sickle cell disease have red blood cells that contain mostly hemoglobin S, an abnormal type of hemoglobin.

Sometimes, these red blood cells become sickle-shaped (crescent-shaped) and have difficulty passing through small blood vessels. When sickle-shaped cells block small blood vessels, less blood can reach that body part. The tissue that does not receive normal blood flow eventually becomes damaged. However, the FDA approved a new sickle cell disease treatment in December 2023. The treatment is called Casgevy, the first medicine approved in the United States that uses CRISPR, a gene editing tool from Vertex Pharmaceuticals and CRISPR Therapeutics. In May 2024, a 12-year-old Black boy, Kendric Cromer, who suffered debilitating pain because of sickle cell disease, became the first patient in the United States to undergo a newly approved gene therapy.

Sickle cell disease has no specific age and affects children like Cali Cole, who was born with the disease and was miraculously cured at four years old, thanks to the help of her younger sister, who is now four. Kendra Cole shared with ESSENCE that her daughter Cali was born with sickle cell disease and received a bone marrow transplant on April 1, 2021, at four years old, curing her of sickle cell disease, thanks to a stem cell donation from her 18-month-old sister Reign (who we had through a year-long process of in-vitro fertilization). The family of five, Kendra, her husband, Lord Cole, and her three children (Cali, Reign, and Valor), bonded to brave through a timeline of medical events relating to sickle cell disease. In 2016, Kendra and Lord began family planning, knowing they wanted to grow their family. Through family planning, they decided to participate in genetic testing, where Kendra learned she had sickle cell trait.

In 2017, their first child, Cali, was born, and the familys medical team at Lurie Childrens Hospital in Chicago, Illinois, informed them that Cali had sickle cell disease, which was determined through newborn screening. From 2017-2021, Cali experienced the following complications due to sickle cell include: Splenic sequestration, Multiple pain crises, Dactylitis, Acute chest syndrome, Extreme constipation, Kidney damage, and Abnormal TCD brain scan results. At the end of 2017, the Cole family feverishly checked the Be the Match bone marrow registry for a potential match and did not find one, so they decided to try another child via IVF to see if it could be a bone marrow match. In 2018, Kendra began the IVF process again, and Reign was born in 2019. In 2021, the Cole family decided to move forward with the bone marrow transplant via stem cell donation of Reign. While Reign and Valor dont have sickle cell disease, they are susceptible to the trait.

Although now Cali is three years post-transplant with no complications and is living a happy, healthy life, sickle cell-free, her family remembers the toll sickle cell disease had on all of them. We spoke with Kendra to understand sickle cell diseases impact on her, her husband, and her children.

ESSENCE: Can you speak to your experience as a caregiver?

Kendra Cole: There were so many moments where there were high highs and lows. Any person who any parent who has a child, you know, they love them with every ounce of your being. At the same time, I felt immense guilt for not knowing my trait status. I often thought to myself, how could I have decided to bring a child into the world and have her experience so much pain early on in her life? I think there were many times throughout those first four years of her life that I felt like I was almost operating in survival mode a little bit. I wouldnt allow myself to be fully vulnerable with my daughter as her mother because I genuinely was just so afraid. But there were so many hospital days where I had to put on a brave face, be calm, and make these tough decisions within an emotionally charged atmosphere.

How can we be more of sickle cell disease in our community?

Sickle cell disease is an inherited blood disorder, so its not something that you can see. And pain is often subjective, right? So its painful to one person and may or may not be that painful to someone else.

Can you speak to the importance of Gene therapy?

Ive been excited about many new developments, specifically gene therapy. Gene therapy is a great advancement in sickle cell disease care and curative options, and there just hasnt been much movement on that in years.

How are you continuing to spread awareness?

Im still active in my local Sickle Cell Disease Association of Illinois chapter, whether through the parent group or our annual awareness walk. Ive also been in contact with several parents whose children want to undergo the bone marrow transplant process. Ive connected with many families and just offered them our story, support, and checking in with them.

Read the original here:
Life After Sickle Cell: A Seven-Year-Old Was Cured Of The Disease Thanks To Her Younger Sister - Essence

Comments Closed|

Hematopoietic stem cell transplantation (HSCT) Market Future Growth Trends, Upcoming Opportunities and … – openPR

June 25th, 2024

Latest Report, titled "Hematopoietic stem cell transplantation (HSCT) Market" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.

The report features a comprehensive table of contents, figures, tables, and charts, as well as insightful analysis. The keyword market has been expanding significantly in recent years, driven by various key factors like increased demand for its products, expanding customer base, and technological advancements. This report provides a comprehensive analysis of the Hematopoietic stem cell transplantation (HSCT) market, including market size, trends, drivers and constraints, competitive aspects, and prospects for future growth.

The report sheds light on the competitive landscape, segmentation, geographical expansion, revenue, production, and consumption growth of the Hematopoietic stem cell transplantation (HSCT) market. The keyword Market Size, Growth Analysis, Industry Trend, and Forecast provides details of the factors influencing the business scope. This report provides future products, joint ventures, marketing strategy, developments, mergers and acquisitions, marketing, promotions, revenue, import, export, CAGR values, the industry as a whole, and the particular competitors faced are also studied in the large-scale market.

Sample Pages of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/1250?utm_source=openpr.com&utm_medium=referral

Key Players Covered In This Report:

Pluristem Therapeutics Inc. CellGenix GmbH Regen Biopharma Inc. Lonza Group Kiadis Pharma Taiga Biotechnologies Inc. Takeda Pharmaceutical Company Limited Escape Therapeutics Inc. Bluebird Bio Inc. Talaris Therapeutics Inc. Marker Therapeutics Inc. Stempeutics Research Pvt Ltd. CBR Systems Inc. Priothera Ltd. Eurobio Scientific Group Otsuka America Pharmaceutical Inc. Pfizer Inc. Sanofi FUJIFILM Holdings Corporation

This Report includes a company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The data points provided are only related to the company's focus related to Hematopoietic stem cell transplantation (HSCT) markets. Leading global Hematopoietic stem cell transplantation (HSCT) market players and manufacturers are studied to give a brief idea about competitions.

Market Segmentation:

By Transplant Type: Allogeneic, Autologous By Indication: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hodgkin lymphoma (HL), Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Others By Application: Bone Marrow Transplant (BMT), Peripheral Blood Stem Cells Transplant (PBSCT), Cord Blood Transplant (CBT) By End User: Hospitals, Specialty Clinics, Others

Overview and Scope of the Report:

This report is centred around the Hematopoietic stem cell transplantation (HSCT) in the worldwide market, with a specific focus on North America, Europe, Asia-Pacific, South America, Middle East, and Africa. The report classifies the market by manufacturers, regions, type, and application. It presents a comprehensive view of the current market situation, encompassing historical and projected market size in terms of value and volume. Additionally, the report covers technological advancements and considers macroeconomic and governing factors influencing the market.

Key Opportunities:

The report examines the key opportunities in the Hematopoietic stem cell transplantation (HSCT) Market and identifies the factors that are driving and will continue to drive the industry's growth. It takes into account past growth patterns, growth drivers, as well as current and future trends.

Buy-Now and Get Up to 25% Discount @ https://www.coherentmarketinsights.com/insight/buy-now/1250

Highlights of Our Report:

Extensive Market Analysis: A deep dive into the manufacturing capabilities, production volumes, and technological innovations within the Hematopoietic stem cell transplantation (HSCT) Market.

Corporate Insights: An in-depth review of company profiles, spotlighting major players and their strategic manoeuvres in the market's competitive arena.

Consumption Trends: A detailed analysis of consumption patterns, offering insight into current demand dynamics and consumer preferences.

Segmentation Details: An exhaustive breakdown of end-user segments, depicting the market's spread across various applications and industries.

Pricing Evaluation: A study of pricing structures and the elements influencing market pricing strategies.

Future Outlook: Predictive insights into market trends, growth prospects, and potential challenges ahead.

Why Should You Obtain This Report?

Statistical Advantage: Gain access to vital historical data and projections for the Hematopoietic stem cell transplantation (HSCT) Market, arming you with key statistics.

Competitive Landscape Mapping: Discover and analyze the roles of market players, providing a panoramic view of the competitive scene.

Insight into Demand Dynamics: Obtain comprehensive information on demand characteristics, uncovering market consumption trends and growth avenues.

Identification of Market Opportunities: Astutely recognize market potential, aiding stakeholders in making informed strategic decisions.

Acquiring this report ensures you are equipped with the most current and trustworthy data, sharpening your market strategies and securing a well-informed stance in the complex domain of the Hematopoietic stem cell transplantation (HSCT) industry. Each report is meticulously prepared, guaranteeing that our clients receive the critical intelligence needed to excel in this evolving market.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1250

Questions Answered by the Report:

(1) Which are the dominant players of the Hematopoietic stem cell transplantation (HSCT) Market? (2) What will be the size of the Hematopoietic stem cell transplantation (HSCT) Market in the coming years? (3) Which segment will lead the Hematopoietic stem cell transplantation (HSCT) Market? (4) How will the market development trends change in the next five years? (5) What is the nature of the competitive landscape of the Hematopoietic stem cell transplantation (HSCT) Market? (6) What are the go-to strategies adopted in the Hematopoietic stem cell transplantation (HSCT) Market?

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

Contact Us: Mr. Shah Coherent Market Insights Pvt. Ltd, U.S.: +1-206-701-6702 U.K.: +44-020-8133-4027 AUS: +61-2-4786-0457 INDIA: +91-848-285-0837 Email: sales@coherentmarketinsights.com

:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.

Read the original:
Hematopoietic stem cell transplantation (HSCT) Market Future Growth Trends, Upcoming Opportunities and ... - openPR

Comments Closed|

‘General Hospital’ star John J York returns to work after ‘aggressive’ cancer treatment – Yahoo Entertainment

June 25th, 2024

"General Hospital" star John J. York got emotional while recounting his long cancer battle.

York, who announced his hiatus from the hit soap opera in September, was a guest on "Good Morning America" and explained that a number of people signed up to donate bone marrow after he announced his cancer diagnosis.

"Everybody has been very welcoming, very supportive," York said before beginning to cry. "And here I go already right off the top cause I cant tell you how nice its been, the support that Ive gotten."

'GENERAL HOSPITAL' ACTOR JOHNNY WACTOR'S KILLER AT LARGE, LAPD SHARES NEW DETAILS ABOUT THREE SUSPECTS

After a routine check-up in December 2022, York was diagnosed with two types of blood and bone marrow cancer: myelodysplastic syndrome and smoldering multiple myeloma.

According to the Mayo Clinic, myelodysplastic syndrome is "a group of disorders caused by blood cells that are poorly formed or don't work properly. Myelodysplastic syndromes result from something amiss in the spongy material inside your bones where blood cells are made (bone marrow)."

READ ON THE FOX NEWS APP

The Mayo Clinic describes smoldering multiple myeloma as a form of multiple myeloma that does not always cause symptoms, explaining "If the myeloma is at an early stage and is growing slowly, you might have regular checkups to monitor the cancer."

"I made the announcement and it has helped. And so many people have joined the registry, just to help to save someone's life," York said, taking a pause in the middle of the statement as he continued to get emotional.

Due to both of York's diagnoses, he required a bone marrow transplant.

LIKE WHAT YOURE READING? CLICK HERE FOR MORE ENTERTAINMENT NEWS

The actor had to undergo seven days of chemotherapy at Vanderbilt University in Tennessee before he was allowed to get on a flight to Los Angeles to film "General Hospital." His first episode back will air on June 19.

After York was told he would have "3-5 years" if he did not undergo treatment, he decided to go the most "aggressive" route by getting a bone marrow transplant and chemotherapy.

"My philosophy was always, One day at a time, lets just get through today,'" he said. "I made the announcement, and it has helped and so many people have joined the registry just to help save someones life."

It took some time for York to find a stem cell donor. He recalled on "Good Morning America" the moment he found a donor.

CLICK HERE TO SIGN UP FOR THE ENTERTAINMENT NEWSLETTER

"She said we found an exact match and I just couldnt talk," York said. "Its just a little bag of blood and fluid, and they put it in my body, 40 minutes later, and now Im this person."

York explained that his cells are "now fighting each other and battling each other and getting to know each other."

"And here we are, back to work," he added. John has appeared on "General Hospital" since 1991.

York's hiatus from the show didn't feel very long to him, but rather felt like he "had a little break."

Original article source: 'General Hospital' star John J York returns to work after 'aggressive' cancer treatment

Read this article:
'General Hospital' star John J York returns to work after 'aggressive' cancer treatment - Yahoo Entertainment

Comments Closed|

Takeaways from AP’s report on access to gene therapies for rare diseases – Yahoo News Canada

June 25th, 2024

The promise of gene therapy looms large for families dealing with rare, genetic disorders. Such treatments offer the possibility of one-time cures.

But families and researchers worry such therapies will remain out of reach.

Collectively, about 350 million people worldwide suffer from rare diseases, most of which are genetic. But each of the 7,000 individual disorders affects perhaps a few in a million people or less. So theres little commercial incentive to develop or bring to market these one-time therapies to fix faulty genes or replace them with healthy ones.

The Associated Press examined what this means for families, scientists and the nascent field of gene therapy.

Here are key takeaways from AP's report.

Families are frustrated, and some try to raise their own funds.

Camden Alderman was diagnosed as a baby with a rare disease called Wiskott-Aldrich syndrome, which is caused by a mutated gene on the X chromosome. It primarily affects boys up to 10 out of every million and can cause frequent infections, eczema and excessive bleeding.

When he was a toddler, doctors removed his spleen because of uncontrolled bleeding. As a young boy, he wound up in the hospital many times and was told he couldnt play baseball.

His mother Robin Alderman recalls one doctor saying: Basically, your sons only chance at a cure is going to be gene therapy.

He also told her researchers werent then accepting U.S. residents into a clinical trial for the treatment, which just kind of broke my heart, she said. There's still no clinical trial he can join, and London-based Orchard Therapeutics stopped investing in an experimental treatment for the condition in 2022.

Lacey Hendersons daughter, 5-year-old Estella, has alternating hemiplegia of childhood, a neurological condition that affects 300 people in the U.S. Estella is cognitively delayed, has limited use of her hands and suffers episodes that temporarily paralyze part or all of her body, Henderson said. Medications can curb symptoms, but theres no cure.

Her Iowa family raises money through a GoFundMe and a website to develop a gene therapy. Theyve brought in around $200,000.

We have three different projects with various researchers, Henderson said. But the problem is everything is underfunded.

Financial disincentives can plague the process.

The amount of work it takes to get from a lab to human testing and through the drug approval process is incredibly expensive, said Dr. Donald Kohn, professor of microbiology, immunology and molecular genetics at the University of California, Los Angeles.

In the last couple of years, he said, investment in gene therapy has largely dried up.

If you have to spend $20 million or $30 million to get approval and you have five or 10 patients a year, its hard to get a return on investment, Kohn said. So we have successful, safe therapies, but its more the financial, economic elements that are limiting them from becoming approved drugs."

Ultimately, most biotechnology companies become public and must focus on shareholder profit, said Francois Vigneault, CEO of the Seattle biotech Shape Therapeutics.

The board is the thing that gets in the way; theyre trying to maximize gain, said Vigneault, whose company is privately held. Thats just greed. Thats just incentive misaligned between corporate company structure and what we should do thats good for the world.

Scientists, nonprofits and patient groups are working toward solutions.

In the U.S., for example, The Bespoke Gene Therapy Consortium was organized by the Foundation for the National Institutes of Health and includes the FDA, various NIH institutes and several drug companies and nonprofits. Its goals include supporting a handful of clinical trials and streamlining regulatory processes.

Researchers are trying to address the problem scientifically. Dr. Anna Greka said the Broad Institute of MIT and Harvard has launched an effort to look at the commonalities behind various conditions or nodes, which can be likened to branches meeting at a tree trunk. Fixing the nodes with gene therapies or other treatments, rather than particular misspellings in DNA responsible for one disorder, could potentially address multiple diseases simultaneously.

What this does is it increases the number of patients who can benefit from the therapy, said Greka, a Broad member.

Still, scientists say these efforts dont negate the larger financial quandary surrounding therapies for rare diseases, and it may be a while before such gene therapies are available to patients worldwide.

This is a massive challenge, and Im not entirely sure were going to be able to overcome it, said Claire Booth of University College London. But we have to give it a go because weve spent decades and millions making these transformative treatments. And if we dont try, then it feels like the end of an era.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Science and Educational Media Group. The AP is solely responsible for all content.

Laura Ungar, The Associated Press

Read more:
Takeaways from AP's report on access to gene therapies for rare diseases - Yahoo News Canada

Comments Closed|

Tunable translation-level CRISPR interference by dCas13 and engineered gRNA in bacteria – Nature.com

June 25th, 2024

Zhang, R., Xu, W., Shao, S. & Wang, Q. Gene silencing through CRISPR interference in bacteria: current advances and future prospects. Front. Microbiol. 12, 18 (2021).

Google Scholar

Han, Y. H., Kim, G. & Seo, S. W. Programmable synthetic biology tools for developing microbial cell factories. Curr. Opin. Biotechnol. 79, 102874 (2023).

Article CAS PubMed Google Scholar

Lv, X. et al. New synthetic biology tools for metabolic control. Curr. Opin. Biotechnol. 76, 102724 (2022).

Article CAS PubMed Google Scholar

Kent, R. & Dixon, N. Contemporary tools for regulating gene expression in bacteria. Trends Biotechnol. 38, 316333 (2020).

Article CAS PubMed Google Scholar

Ren, J., Lee, J. & Na, D. Recent advances in genetic engineering tools based on synthetic biology. J. Microbiol. 58, 110 (2020).

Article CAS PubMed Google Scholar

Qi, L. S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 11731183 (2013).

Article CAS PubMed PubMed Central Google Scholar

Zhang, X. et al. Multiplex gene regulation by CRISPR-ddCpf1. Cell Discov. 3, 19 (2017).

Article Google Scholar

Na, D. et al. Metabolic engineering of Escherichia coli using synthetic small regulatory RNAs. Nat. Biotechnol. 31, 170174 (2013).

Article CAS PubMed Google Scholar

Abudayyeh, O. O. et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science 353, aaf5573 (2016).

Article PubMed PubMed Central Google Scholar

East-Seletsky, A. et al. Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature 538, 270273 (2016).

Article CAS PubMed PubMed Central Google Scholar

OConnell, M. R. Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPRCas systems. J. Mol. Biol. 431, 6687 (2019).

Article PubMed Google Scholar

Charles, E. J. et al. Engineering improved Cas13 effectors for targeted post-transcriptional regulation of gene expression. Preprint bioRxiv https://doi.org/10.1101/2021.05.26.445687 (2021).

Otoupal, P. B., Cress, B. F., Doudna, J. A. & Schoeniger, J. S. CRISPR-RNAa: targeted activation of translation using dCas13 fusions to translation initiation factors. Nucleic Acids Res. https://doi.org/10.1093/nar/gkac680 (2022).

Shmakov, S. et al. Discovery and functional characterization of diverse class 2 CRISPR-Cas systems. Mol. Cell 60, 385397 (2015).

Article CAS PubMed PubMed Central Google Scholar

Smargon, A. A. et al. Cas13b is a type VI-B CRISPR-associated RNA-guided rnase differentially regulated by accessory proteins Csx27 and Csx28. Mol. Cell 65, 618630.e7 (2017).

Article CAS PubMed PubMed Central Google Scholar

Yan, W. X. et al. Cas13d is a compact RNA-targeting type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol. Cell 70, 327339.e5 (2018).

Article CAS PubMed PubMed Central Google Scholar

Hu, Y. et al. Metagenomic discovery of novel CRISPR-Cas13 systems. Cell Discov. 8, 107 (2022).

Article CAS PubMed PubMed Central Google Scholar

Liu, L. et al. The molecular architecture for RNA-guided RNA cleavage by Cas13a. Cell 170, 714726.e10 (2017).

Article CAS PubMed Google Scholar

Konermann, S. et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173, 665676.e14 (2018).

Article CAS PubMed PubMed Central Google Scholar

Eichner, H., Karlsson, J. & Loh, E. The emerging role of bacterial regulatory RNAs in disease. Trends Microbiol. 30, 959972 (2022).

Article CAS PubMed Google Scholar

Fujita, S., Tsumori, Y., Makino, Y., Saito, M. & Kawano, M. Development of multiplexing gene silencing system using conditionally induced polycistronic synthetic antisense RNAs in Escherichia coli. Biochem. Biophys. Res. Commun. 556, 163170 (2021).

Article CAS PubMed Google Scholar

Yang, Y., Lin, Y., Li, L., Linhardt, R. J. & Yan, Y. Regulating malonyl-CoA metabolism via synthetic antisense RNAs for enhanced biosynthesis of natural products. Metab. Eng. 29, 217226 (2015).

Article CAS PubMed Google Scholar

Wu, Y. et al. Design of a programmable biosensor-CRISPRi genetic circuits for dynamic and autonomous dual-control of metabolic flux in Bacillus subtilis. Nucleic Acids Res. 48, 9961009 (2020).

Article CAS PubMed Google Scholar

Tian, J. et al. Developing an endogenous quorum-sensing based CRISPRi circuit for autonomous and tunable dynamic regulation of multiple targets in Streptomyces. Nucleic Acids Res. 48, 81888202 (2020).

Article CAS PubMed PubMed Central Google Scholar

Vento, J. M., Crook, N. & Beisel, C. L. Barriers to genome editing with CRISPR in bacteria. J. Ind. Microbiol. Biotechnol. 46, 13271341 (2019).

Article CAS PubMed Google Scholar

Wessels, H.-H. et al. Prediction of on-target and off-target activity of CRISPRCas13d guide RNAs using deep learning. Nature Biotechnol. https://doi.org/10.1038/s41587-023-01830-8 (2023).

Cheng, X. et al. Modeling CRISPR-Cas13d on-target and off-target effects using machine learning approaches. Nat. Commun. 14, 752 (2023).

Wessels, H. H. et al. Massively parallel Cas13 screens reveal principles for guide RNA design. Nat. Biotechnol. 38, 722727 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhang, C. et al. Structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d. Cell 175, 212223.e17 (2018).

Article CAS PubMed PubMed Central Google Scholar

Irastortza-Olaziregi, M. & Amster-Choder, O. Coupled transcription-translation in prokaryotes: an old couple with new surprises. Front. Microbiol. 11, 624830 (2021).

De Lay, N., Schu, D. J. & Gottesman, S. Bacterial small RNA-based negative regulation: Hfq and its accomplices. J. Biol. Chem. 288, 79968003 (2013).

Article PubMed PubMed Central Google Scholar

Prvost, K., Desnoyers, G., Jacques, J.-F., Lavoie, F. & Mass, E. Small RNA-induced mRNA degradation achieved through both translation block and activated cleavage. Genes Dev. 25, 385396 (2011).

Article PubMed PubMed Central Google Scholar

Tian, T., Kang, J. W., Kang, A. & Lee, T. S. Redirecting metabolic flux via combinatorial multiplex CRISPRi-mediated repression for isopentenol production in Escherichia coli. ACS Synth. Biol. 8, 391402 (2019).

Article CAS PubMed Google Scholar

Rousset, F. et al. Genome-wide CRISPR-dCas9 screens in E. coli identify essential genes and phage host factors. PLoS Genet. 14, 128 (2018).

Article Google Scholar

Dwijayanti, A., Storch, M., Stan, G.-B. & Baldwin, G. S. A modular RNA interference system for multiplexed gene regulation. Nucleic Acids Res. 50, 17831793 (2022).

Article CAS PubMed PubMed Central Google Scholar

Noh, M., Yoo, S. M., Kim, W. J. & Lee, S. Y. Gene expression knockdown by modulating synthetic small RNA expression in Escherichia coli. Cell Syst. 5, 418426.e4 (2017).

Article CAS PubMed Google Scholar

Noh, M., Yoo, S. M., Yang, D. & Lee, S. Y. Broad-spectrum gene repression using scaffold engineering of synthetic sRNAs. ACS Synth. Biol. 8, 14521461 (2019).

Article CAS PubMed Google Scholar

Vigouroux, A., Oldewurtel, E., Cui, L., Bikard, D. & Teeffelen, S. Tuning dCas9s ability to block transcription enables robust, noiseless knockdown of bacterial genes. Mol. Syst. Biol. 14, 114 (2018).

Article Google Scholar

Byun, G., Yang, J. & Seo, S. W. CRISPRi-mediated tunable control of gene expression level with engineered single-guide RNA in Escherichia coli. Nucleic Acids Res. 51, 46504659 (2023).

Article CAS PubMed PubMed Central Google Scholar

Fontana, J., Dong, C., Ham, J. Y., Zalatan, J. G. & Carothers, J. M. Regulated expression of sgRNAs tunes CRISPRi in E. coli. Biotechnol. J. 13, 1800069 (2018).

Article Google Scholar

Li, X. T. et al. TCRISPRi: tunable and reversible, one-step control of gene expression. Sci. Rep. 6, 112 (2016).

Article Google Scholar

Elowitz, M. B., Levine, A. J., Siggia, E. D. & Swain, P. S. Stochastic gene expression in a single cell. Science 297, 11831186 (2002).

Article CAS PubMed Google Scholar

Wang, J., Li, C., Jiang, T. & Yan, Y. Biosensor-assisted titratable CRISPRi high-throughput (BATCH) screening for over-production phenotypes. Metab. Eng. 75, 5867 (2023).

Article CAS PubMed Google Scholar

Hawkins, J. S. et al. Mismatch-CRISPRi reveals the co-varying expression-fitness relationships of essential genes in Escherichia coli and Bacillus subtilis. Cell Syst. 11, 523535.e9 (2020).

Article CAS PubMed PubMed Central Google Scholar

Jost, M. et al. Titrating gene expression using libraries of systematically attenuated CRISPR guide RNAs. Nat. Biotechnol. 38, 355364 (2020).

Article CAS PubMed PubMed Central Google Scholar

Zhang, B. et al. Two HEPN domains dictate CRISPR RNA maturation and target cleavage in Cas13d. Nat. Commun. 10, 2544 (2019).

Nakashima, N., Tamura, T. & Good, L. Paired termini stabilize antisense RNAs and enhance conditional gene silencing in Escherichia coli. Nucleic Acids Res. 34, e138e138 (2006).

Article PubMed PubMed Central Google Scholar

Hoffart, E. et al. High substrate uptake rates Empower Vibrio natriegens as production host for industrial biotechnology. Appl. Environ. Microbiol. 83, e01614e01617 (2017).

Kim, S. K., Seong, W., Han, G. H., Lee, D. H. & Lee, S. G. CRISPR interference-guided multiplex repression of endogenous competing pathway genes for redirecting metabolic flux in Escherichia coli. Microb. Cell Fact. 16, 115 (2017).

Article Google Scholar

Hgler, M., Menendez, C., Schgger, H. & Fuchs, G. Malonyl-coenzyme A reductase from Chloroflexus aurantiacus, a key enzyme of the 3-hydroxypropionate cycle for autotrophic CO2 fixation. J. Bacteriol. 184, 24042410 (2002).

Article PubMed PubMed Central Google Scholar

Kumar, V., Ashok, S. & Park, S. Recent advances in biological production of 3-hydroxypropionic acid. Biotechnol. Adv. 31, 945961 (2013).

Article CAS PubMed Google Scholar

Lee, J. H. et al. Efficient conversion of acetate to 3-hydroxypropionic acid by engineered Escherichia coli. Catalysts 8, 525 (2018).

Lai, N., Luo, Y., Fei, P., Hu, P. & Wu, H. One stone two birds: biosynthesis of 3-hydroxypropionic acid from CO2 and syngas-derived acetic acid in Escherichia coli. Synth. Syst. Biotechnol. 6, 144152 (2021).

Article CAS PubMed PubMed Central Google Scholar

Park, J. H., Jang, Y.-S., Lee, J. W. & Lee, S. Y. Escherichia coli W as a new platform strain for the enhanced production of l-valine by systems metabolic engineering. Biotechnol. Bioeng. 108, 11401147 (2011).

Article CAS PubMed Google Scholar

See the rest here:
Tunable translation-level CRISPR interference by dCas13 and engineered gRNA in bacteria - Nature.com

Comments Closed|

U.S. CRISPR And Cas Genes Market Size to Hit USD 8.59 Billion by 2033 – BioSpace

June 25th, 2024

According to latest report, the U.S. CRISPR and cas genes market size was estimated at USD 1.85 billion in 2023 and is projected to hit around USD 8.59 billion by 2033, growing at a CAGR of 16.6% during the forecast period from 2024 to 2033.

Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/8491

Therapeutic applications of CRISPR and Cas genes, rising significance for gene editing, and the introduction of anti-CRISPR proteins are boosting market growth. Moreover, CRISPR and Cas genes provide growth prospects for developing novel cancer therapies that boost market expansion.

U.S. CRISPR and Cas genes market accounted for a 63.0% share in the global CRISPR and Cas genes market in 2023. CRISPR technology is preferred for treating various diseases, including cancer and inflammatory and infectious diseases, making it favorable for future biomedical therapeutics. It revolutionizes cancer treatment by enhancing Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy. Unlike traditional methods, the next generation of CAR-T therapies utilizes CRISPR to improve the precision and efficiency of therapeutic and manufacturing processes. This advancement allows for accurate delivery of CAR genes into T-cell DNA, a significant improvement over viral vectors that randomly insert genes. These features of CRISPR-Cas increase its demand in the market.

Furthermore, the increasing investment from government bodies, funding agencies, and biotechnology companies in genomic research is poised to impact the CRISPR market significantly. International funding organizations such as the NIH and Wellcome Trust play a crucial role by providing financial support for genetic studies. This substantial funding is expected to drive the utilization of genetic editing tools in the country, shaping the landscape of the CRISPR market. Furthermore, a report published in June 2022 stated that the U.S. government granted USD 639.5 million to Human Genome Research Institute for R&D in 2022. The institute further requested USD 629.6 million as funding for 2023.

U.S. CRISPR And Cas Genes Market Key Takeaways

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8491

Global CRISPR & Cas Genes Market Size and share 2024 to 2033

The global CRISPR And Cas Genes market size was USD 3.11 billion in 2023, calculated at USD 3.64 billion in 2024 and is expected to reach around USD 15.15 billion by 2033, expanding at a CAGR of 17.16% from 2024 to 2033. North America dominated the market and accounted for the highest revenue share of 39.17% in 2023.

Personalized your customization here@

https://www.novaoneadvisor.com/report/customization/8491

What is CRISPR, the powerful genome-editing tool?

CRISPR-Cas9 is a simple yet powerful tool for editing genomes. It enables researchers to easily alter DNA sequences and modify gene function.

CRISPR is a powerful tool for editing genomes, meaning it allows researchers to easily alter DNA sequences and modify gene function. It has many potential applications, including correcting genetic defects, treating and preventing the spread of diseases, and improving the growth and resilience of crops. However, despite its promise, the technology also raises ethical concerns.

In popular usage, "CRISPR" (pronounced "crisper") is shorthand for "CRISPR-Cas9." CRISPRs are specialized stretches of DNA, and the protein Cas9 where Cas stands for "CRISPR-associated" is an enzyme that acts like a pair of molecular scissors, capable of cutting strands of DNA.

CRISPR technology was adapted from the natural defense mechanisms of bacteria and archaea, a domain of relatively simple single-celled microorganisms. These organisms use CRISPR-derived RNA, a molecular cousin to DNA, and various Cas proteins to foil attacks by viruses. To foil attacks, the organisms chop up the DNA of viruses and then stow bits of that DNA in their own genome, to be used as a weapon against the foreign invaders should those viruses attack again. When the components of CRISPR are transferred into other, more complex, organisms, those components can then manipulate genes, a process called "gene editing."

U.S. CRISPR And Cas Genes Market Concentration & Characteristics

The presence of several companies in the U.S. CRISPR And CAS Genes market contributed to its fragmented landscape. Moreover, companies are leveraging CRISPR editing in the human genome, offering growth opportunities in academic and pharmaceutical research.

By introducing innovative CRISPR-based therapies, companies have the potential to attract customers, drive revenue growth, and enhance patient outcomes significantly. Utilizing CRISPR technology in the development of advanced therapies can assist companies in differentiating themselves in the market, meet patients' evolving requirements, and contribute to personalized medicine. This offers a promising path for using cutting-edge therapies and advancement in personalized medicine.

Companies like CRISPR Therapeutics, Vertex Pharmaceuticals, Intellia Therapeutics, and Regeneron Pharmaceuticals have engaged in strategic partnerships to drive innovation in precision medicine. These collaborations involve sharing resources, expertise, and technologies to develop novel treatments that target genetic disorders at their root cause. Numerous biotechnological and pharmaceutical companies focus on M&A activities that showcase crucial aspects of strategic management that enable companies to facilitate growth, restructuring, and enhancing competitive positions within the industry

Various biotechnology and CRISPR-based therapeutics companies focus on providing services such as cell line engineering and design tools that help in research activities undertaken by institutions and other companies. This approach increases their customer base and enables them to sustain their position in the industry.

Increasing focus on regional expansion by key manufacturers serves a wide range of customers and capitalizes on geographical industry growth opportunities. This approach allows companies to strengthen their presence in different regions, adapt to local market needs, and enhance their market share by targeting diverse customer segments.

Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8491

By Product & Service Insights

In 2023, the product segment held the largest market share of 79.11%. This growth was fueled by the efforts of institutions and key companies to increase research and development activities. This comprises kits& enzymes such as CAS9, CRISPR libraries, antibodies, design tools, and more. Moreover, Vector-based CAS9 products facilitate research experiments, signifying the use of CRISPR/Cas for gene editing. Such applications shift the focus of manufacturers to develop these products, further expanding market growth. Epic Bio unveiled the GEMS (Gene Expression Modulation System) platform in 2022, which offers precise gene expression modification. The GEMS platform contains a vast library of newly discovered modulators combined with advanced functional and computational genomics capabilities. It enables the rapid design of guide RNAs highly targeted to specific genes.

From 2024 to 2033, the services segment is expected to experience the most rapid compound annual growth rate. This growth is fueled by the rising number of licensing agreements with biotech firms, which offer services ranging from cell line engineering and beyond. Moreover, CRISPR-based gene editing companies focus on offering advanced services to fulfill the unmet demand for this market. For instance, in August 2022, Creative Biogene introduced one-stop microbial genome editing services for knock-in, knockout, and foreign gene insertion using a variety of bacteria. These microbial genome editing services maximize customers microbial gene sequence efficiency and minimize off-target effects using the advanced CRISPR/Cas 9 platform.

By Application Insights

The biomedical application segment held the largest share of 92.25% in 2023, owing to the increasing popularity of CRISPR/Cas9 genome editing technology in several areas of biomedical sciences. The market is experiencing profitable growth opportunities thanks to the emergence of different CRISPR-based therapies to treat chronic conditions such as cancer, diabetes, blood disorders, and infectious diseases. Moreover, regulatory approval of these therapies is driving the segments growth. For instance, in December 2023, the US FDA approved Casgevy therapy for sickle cell anemia. Casgevy is the first FDA-approved therapy utilizing CRISPR/Cas9, a genome editing technology.

The agriculture segment will exhibit the quickest compound annual growth rate (CAGR) between 2024 and 2033. The rise in awareness of CRISPR-based gene editing in the agriculture sector has led to increasing adoption improvement in crop production. There is an increase in research studies on agriculture products using CRISPR technology. This trend will expand the growth trajectory of this segment.

By End-use Insights

The biotechnology and pharmaceutical companies segment dominated the market with a share of 50.19% in 2023, owing to the increasing development of CRISPR-based products by major biotechnology and pharmaceutical companies for drug and therapy development. The growing adoption of CRISPR technology in these sectors significantly influences the market landscape and drives revenue growth. Additionally, the rise in the number of companies offering gene and gene-editing products and services in recent years is further fueling the revenue growth within this segment.

The academic and government research institutes are anticipated to grow at a CAGR of 16.1% over the forecast period. The increased research and numerous genomics and gene editing studies in academic and government institutes have increased the demand for CRISPR-Cas9. This surge in research activities focusing on gene engineering and its applications is anticipated to drive rapid growth in the forecast period.

Browse More Trending Reports

Cell Separation Market: The global cell separation market size was exhibited at USD 9.11 billion in 2023 and is projected to hit around USD 23.59 billion by 2033, growing at a CAGR of 9.98% during the forecast period of 2024 to 2033.

Cell and Gene Therapy Market: The global cell and gene therapy market size was estimated at USD 18.13 billion in 2023 and is projected to hit around USD 97.33 billion by 2033, growing at a CAGR of 18.3% during the forecast period from 2024 to 2033.

U.S. Genome Editing Market: The U.S. genome editing market size was estimated at USD 3.55 billion in 2023 and is projected to hit around USD 16.49 billion by 2033, growing at a CAGR of 16.6% during the forecast period from 2024 to 2033.

Gene Expression Market : The global gene expression market size was estimated at USD 13.85 billion in 2023 and is projected to hit around USD 37.35 billion by 2033, growing at a CAGR of 37.35% during the forecast period from 2024 to 2033.

Genome Editing Market: The global genome editing market size was valued at USD 8.45 billion in 2023 and is anticipated to reach around USD 40.48 billion by 2033, growing at a CAGR of 16.96% from 2024 to 2033.

Biotechnology Market: The global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.

Cell & Gene Therapy Bioanalytical Testing Services Market : The global cell & gene therapy bioanalytical testing services market size was valued at USD 585.19 million in 2023 and is projected to surpass around USD 1,194.92 million by 2033, registering a CAGR of 7.4% over the forecast period of 2024 to 2033.

U.S. Gene Synthesis Market: The U.S. Gene Synthesis market size was valued at USD 700.90 million in 2023 and is projected to surpass around USD 3,118.73 million by 2033, registering a CAGR of 16.1% over the forecast period of 2024 to 2033.

U.S. Clinical Trials Market : The U.S. clinical trials market size was valued at USD 25.81 billion in 2023 and is projected to surpass around USD 41.57 billion by 2033, registering a CAGR of 4.88% over the forecast period of 2024 to 2033.

U.S. CRISPR And Cas Genes Market Recent Developments

U.S. CRISPR And Cas Genes Market Top Key Companies:

U.S. CRISPR And Cas Genes Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. CRISPR And Cas Genes market.

By Product & Service

By Application

By End-use

Immediate Delivery Available | Buy This Premium Research

https://www.novaoneadvisor.com/report/checkout/8491

Frequently Asked Questions

Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.novaoneadvisor.com/report/checkout/8491

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818

Email: sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com

See more here:
U.S. CRISPR And Cas Genes Market Size to Hit USD 8.59 Billion by 2033 - BioSpace

Comments Closed|

Seven CRISPR companies to watch in 2024 – Labiotech.eu

June 25th, 2024

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a gene-editing technology that allows scientists to modify DNA with unprecedented precision. Discovered in the early 2010s, CRISPR technology leverages a natural defense mechanism used by bacteria to protect against viral infections. The system uses a guide RNA to direct the Cas9 enzyme to a specific location in the genome, where it creates a double-strand break. This break can then be repaired by the cells natural mechanisms, allowing for the addition, deletion, or modification of genetic material. CRISPR companies are seeing more and more success in the clinic and the market is growing.

CRISPR has rapidly become one of the most powerful tools in genetic engineering, enabling precise changes to the DNA. Its applications are not limited to medicine, which will be our focus in this article, as it also allows the creation of crops with desirable traits in agriculture for instance.

In recent years, the field of CRISPR technology has improved and different forms of the technology are now being leveraged by biotech companies. Prime editing and base editing are innovative CRISPR-related technologies aiming to improve the versatility and precision of therapies.

After CRISPR Therapeutics and Vertex Pharmaceuticals collaborative success leading to CASGEVYs approval by the U.S. Food and Drug Administration (FDA) and Editas Medicines promising efforts to treat blindness, here are eight companies keeping the CRISPR field dynamic.

Beam Therapeutics was founded in 2017, and is headquartered in Cambridge, Massachusetts. The CRISPR technology company develops precision genetic medicines using its proprietary base editing technology.

The company went public on NASDAQ in February 2020 and has raised a total of $689 million since its creation according to Crunchbase.

Beams base editing technology distinguishes itself by focusing on single-base alterations, which can correct mutations at the nucleotide level. This precision reduces the risk of off-target effects and enhances the potential for treating a wide range of genetic disorders. The companys base editing platform includes the REPAIR (adenosine to inosine) and RESCUE (cytosine to uracil) systems for RNA editing, enabling targeted genetic modifications.

Beam Therapeutics has several key candidates in various stages of development:

Eligo Bioscience is a French company founded in 2014. The company focuses on precision gene editing of the microbiome to treat diseases driven by bacterial genes. Eligo Bioscience leverages its proprietary Gene Editing of the Microbiome (GEM) platform to develop therapies that target and modify specific bacterial populations. Eligo Bioscience recently raised $30 million in a series B funding led by Sanofi Ventures.

The companys GEM platform uses engineered bacteriophages to deliver CRISPR-Cas systems directly to specific bacteria within the microbiome. This approach allows for the precise elimination of pathogenic bacteria or the correction of harmful bacterial genes without disrupting the overall balance of the microbiome. By targeting bacterial genes in vivo, Eligos technology aims to address various diseases associated with microbiome dysbiosis, including antibiotic-resistant infections and chronic diseases.

Unlike broad-spectrum antibiotics, which indiscriminately kill bacteria and disrupt the microbiome, Eligos technology selectively targets pathogenic bacteria or genes within the microbiome. This precision reduces collateral damage to beneficial bacteria which helps maintain a healthy microbiome.

In January, Xavier Duportet, chief executive officer (CEO) of the company, was our guest on the Beyond Biotech podcast to talk about its flagship product EB005 targeting acne vulgaris. This candidate is on track to reach the clinic and expand its application to oncology.

Founded in 2018 and headquartered in South San Francisco, California, Epic Bio is focused on developing therapies to modulate gene expression in vivo using its proprietary Gene Expression Modulation System (GEMS) platform. The company launched in 2022 with a $55 million series A round.

Epic Bios approach combines a miniature DNA-binding protein called CasMINI with customized guide RNAs and a wide array of modulator proteins. CasMINI, licensed from Stanford University, is the smallest Cas protein to date, less than half the size of Cas9 and Cas12a, allowing for efficient delivery using adeno-associated virus (AAV) vectors. This platform enables precise gene modulation, expanding the potential for treating a variety of genetic diseases.

The CasMINI protein is engineered to function effectively in cells and is small enough to be delivered in vivo using AAV vectors. This compact size and robust functionality make it possible to target a wide range of tissues and organs with high precision.

Epic Bios pipeline is still preclinical and targets a wide variety of diseases. The companys lead candidate targets facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder characterized by progressive muscle weakness and wasting. The company also develops candidates for heterozygous familial hypercholesterolemia (HeFH), a genetic disorder characterized by high cholesterol levels, and retinitis pigmentosa, a group of inherited disorders that cause progressive retinal degeneration, leading to vision loss.

Locus Biosciences is a biotechnology company founded in 2015 and headquartered in Morrisville, North Carolina. The company specializes in developing precision antibacterial therapies using CRISPR-Cas3-enhanced bacteriophage technology, known as crPhage. Locus Biosciences most recent funding is a $35 million series B round in 2022.

The company employs a CRISPR-Cas3 system for its antibacterial therapies. Unlike the more commonly used Cas9, Cas3 destroys the DNA of target bacteria irreversibly, making it highly effective against antibiotic-resistant strains. This technology is delivered using engineered bacteriophages, viruses that specifically target bacteria, allowing the preservation of the microbiome.

The CRISPR-Cas3 system sets Locus apart by offering a genetic chainsaw approach, which differs from the genetic scissors approach of CRISPR-Cas9. Cas3s ability to degrade large segments of DNA makes it particularly effective for combating multi-drug resistant bacteria.

Locus lead candidate LBP-EC01 is currently in phase 2/3 and targets Escherichia coli (E. coli) infections. E. coli is a type of bacteria commonly found in the intestines of humans and animals. While most strains are harmless and part of the normal gut flora, some can cause serious infections. E. coli infections can occur through the consumption of contaminated food or water or by contact with animals or person-to-person spread.

LBP-SA01, another candidate in the companys pipeline, targets staphylococcus aureus infections. While it often exists harmlessly, it can cause a wide range of infections if it enters the body through a cut or a wound.

Founded in 2017 and headquartered in Brisbane, California, the company leverages its proprietary CRISPR platform for therapeutics and diagnostics. Like Caribou Biosciences we mentioned last week, this CRISPR company was co-founded by Nobel laureate Jennifer Doudna.

Mammoth Biosciences has raised substantial funding, including a $150 million series D financing round in 2021, which has elevated its status to a unicorn with a valuation of over $1 billion.

Mammoth Biosciences focuses on the discovery and engineering of novel CRISPR systems, specifically the ultra-small Cas14 and Cas (phi) enzymes. These systems are smaller and have an increased temperature stability, and faster reaction, which enhance their effectiveness in in vivo genome editing and diagnostics.

The use of Cas14 and Cas enzymes allows Mammoth Biosciences to develop CRISPR-based solutions that are more efficient and versatile. The smaller size of these enzymes enables easier delivery into cells, especially for diseases that affect the central nervous system.

Mammoth Biosciences is developing both therapeutic and diagnostic products. The companys therapeutic pipeline is still in the preclinical and research stages, and the indications of its candidates are mostly undisclosed.

Additionally, Mammoth has its diagnostic platform, the DETECTR platform, which is a CRISPR-based detection system.

Prime Medicine was founded in 2019 and is headquartered in Cambridge, Massachusetts. The company focuses on developing gene editing therapies using its proprietary prime editing technology. Prime editing aims to address the root causes of genetic diseases by precisely correcting mutations at their source.

The company launched with $315 million in financing, comprising a $115 million series A round followed by a $200 million series B round.

Prime Medicine utilizes prime editing, a novel gene editing technology that acts like a DNA word processor to search and replace disease-causing genetic sequences. Unlike traditional CRISPR methods, prime editing does not create double-strand breaks in DNA, which reduces the risk of unintended modifications. This technology can correct a wide range of genetic mutations, making it an interesting and promising tool for developing therapies for genetic disorders.

The technology employs a fusion protein combining a Cas protein with a reverse transcriptase enzyme and a guide RNA (pegRNA) to direct the correction process. This approach allows for highly specific and predictable edits at the targeted genomic location, minimizing off-target effects.

Prime Medicine is advancing several preclinical programs targeting various genetic diseases: Wilsons disease, preventing the body from properly eliminating excess copper and leading to severe brain and liver issues, glycogen storage disease, and retinitis pigmentosa, among others.

Primes most advanced program, however, is an ex vivo therapy in phase 1/2 targeting chronic granulomatous disease, an inherited immunodeficiency disorder that affects the bodys ability to fight certain infections.

Scribe Therapeutics is a molecular engineering company founded in 2018 and headquartered in Alameda, California. The company focuses on developing advanced CRISPR-based genetic medicines and collaborates with industry leaders such as Biogen or Sanofi.

The company recently completed a $100 million Series B financing round led by Avoro Ventures and Avoro Capital Advisors.

Scribe Therapeutics leverages its CRISPR by design platform, which includes custom-engineered CRISPR enzymes. By optimizing the CRISPR enzymes for greater efficiency, Scribes XE technology can achieve more precise and robust gene edits.Scribes XE platform features advancements in delivery technologies, such as viral vectors and lipid nanoparticles, that are optimized for delivering CRISPR components into target cells and tissues in vivo.

The CRISPR company works on several therapeutic areas hand in hand with key players in the industry. Scribe is collaborating with Biogen to develop CRISPR-based therapies for amyotrophic lateral sclerosis (ALS). In partnership with Sanofi, Scribe is also working on genetically modifying natural killer (NK) cell therapies for cancer treatment. The XE platforms high specificity and efficacy make it ideal for engineering these cells to target and eliminate cancer cells effectively.

SNIPR Biome was founded in 2017 and is headquartered in Copenhagen, Denmark. The company specializes in developing CRISPR-based microbial gene therapies aimed at precisely targeting and eradicating pathogenic bacteria, including antibiotic-resistant strains.

SNIPR Biome has raised notable funding including one of Europes largest series A rounds, securing $50 million.

SNIPR Biomes primary technology involves CRISPR-Guided Vectors (CGV), which deliver CRISPR components into bacterial cells via engineered bacteriophages. These vectors create double-stranded breaks in the DNA of target bacteria, leading to rapid and specific bacterial killing. This approach is designed to preserve beneficial microbiota while targeting harmful pathogens, particularly those resistant to conventional antibiotics.

SNIPR001 is the companys lead candidate, a CRISPR therapy targeting E. coli, including antibiotic-resistant strains. SNIPR001 is designed to prevent bloodstream infections in patients undergoing hematopoietic stem cell transplants, who are particularly vulnerable to such infections. Positive interim results from phase 1 clinical trials showed that SNIPR001 was well-tolerated and effectively reduced gut E. coli levels in treated individuals.

The CRISPR technology market is experiencing robust growth and substantial investments. In 2024, the global market was valued at approximately $3.78 billion and is projected to reach around $9.34 billion by 2029, growing at a compound annual growth rate (CAGR) of 19.9%. This promising outlook for the CRISPR market is driven not only by the recent success of companies like Vertex and CRISPR Therapeutics but also by the emergence of more refined versions of the CRISPR technology.

While there is no doubt CRISPR has a bright future ahead, the market faces several challenges. The high costs associated with CRISPR technology are one of the main obstacles to its democratization in the future. Ethical concerns regarding genetic modifications and regulatory hurdles are also significant obstacles as ethics and law always move slower than technology.

More broadly, the gene editing and engineering scenes are moving fast, and technologies such as epigenetic editing and gene writing with companies such as Chroma Medicine and Tessera Therapeutics show significant potential.

Partnering 2030: The Biotech Perspective 2023

Download Inparts latest report revealing the priorities of out-licensers worldwide.

Here is the original post:
Seven CRISPR companies to watch in 2024 - Labiotech.eu

Comments Closed|

In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer – Nature.com

June 25th, 2024

Direct in vivo CRISPR gene editing in the mouse pancreas

To functionally test putative PDAC cancer genes in vivo, we employed a multiplexed CRISPR/Cas9 genome editing approach to generate knock-out clones directly in the pancreatic epithelium of tumor-prone mice. We used conditional Lox-Stop-Lox-(LSL)-KrasG12D and LSL-Cas9-GFP mice crossed to the pancreas-specific PDX1-Cre driver line (termed KC mice) and injected an adeno-associated virus that expresses a sgRNA and the H2B-RFP fluorescent marker (AAV-sgRNA-RFP) (Fig.1a). Cre-mediated excision of Lox-Stop-Lox cassettes resulted in expression of oncogenic KrasG12D, Cas9 and GFP and formation of hundreds of cytokeratin19 positive (CK19) pancreatic intraepithelial neoplasia (PanIN) precursor lesions, which can be lineage-traced by virtue of red fluorescence (Supplementary Fig.1a, b). To validate the efficiency of CRISPR/Cas9-mediated mutagenesis, we injected sgRNAs targeting GFP, which revealed a knock-out efficacy of 786% (Supplementary Fig.1c).

A Experimental design of the in vivo PDAC CRISPR screen, showing gene selection from long-tail mutations, pancreatic injection of AAV libraries and tumor sequencing. B Tumor-free survival of Pdx1-Cre;LSL-KrasG12D;LSL-Cas9-GFP mice transduced with a sgRNA library targeting putative pancreatic cancer genes (n=23) or a control sgRNA library (n=13) C Representative whole-mount, H&E and immunofluorescent images of an H2B-RFP+ pancreatic PDAC-library tumor: Scale bar 2mm. H&E image: scale bar 250m. Representative immunofluorescence image shows H2B-RFP and CK19 expression. Scale bar 50m. Similar results were observed in all collected tumor. D Representative pie charts showing tumor suppressor genes with enriched sgRNAs in tumor DNA obtained from three different pancreatic tumors and a control-transduced pancreas with multifocal PanINs. E Bar graph showing putative tumor suppressor genes with enriched sgRNAs in tumor DNA obtained from the PDAC mouse model (sgRNA enriched per tumors are indicated by color).

KC mice exhibited rapid growth of pre-invasive PanINs precursor lesions but showed very slow progression to invasive PDAC with a median latency of 14 months (Fig.1b). Additional genetic alterations such as loss of transformation-related protein 53 (Trp53), p16Ink4a, Lkb1 or inactivation of TGF- signaling was previously shown to cooperate with KrasG12D and induces rapid PDAC development within 3-5 month16,17,18,19,20. To test whether our direct in vivo CRISPR approach can reveal genetic interactions, we recapitulated cooperation between oncogenic KrasG12D and loss of p53 (Trp53). Indeed, Cas9-mediated ablation of Trp53 in KC mice triggered rapid PDAC formation with a median latency of 14 weeks, while littermates transduced with scrambled control sgRNAs remained cancer-free for over 1 year (Supplementary Fig.1d). This is in line with previous efforts using CRISPR/Cas9 gene editing in KRasG12D mice21,22 and demonstrates that this approach can be used to test for genetic cooperation between PDAC genes.

In pancreatic cancer, 125 genes show recurrent somatic mutations6,7. To assess these genes in vivo, we established a sgRNA library targeting the corresponding mouse orthologs (4 sgRNAs/gene; 500 sgRNAs) and a library of 420 non-targeting control sgRNAs (Supplementary Data1). Of note, we did not include sgRNAs targeting well-established PDAC driver genes such as Trp53 or Smad416,17,18,19,20.

Next, we optimized the parameters for an in vivo CRISPR screen. Using a mixture of AAV-GFP and AAV-RFP, we determined the viral titer that transduces the pancreatic epithelium at clonal density (MOI<1). Higher viral titers were associated with double infections, whereas a 15% overall transduction level minimized double infections while generating necessary clones sufficient to screen (Supplementary Fig.1e). Using multicolor Rosa26-Lox-Stop-Lox(R26-LSL)-Confetti Cre-reporter mice, we next determined the viral titer required to generate thousands of discrete clones within the pancreatic epithelium (Supplementary Fig.1f). Thus, at a transduction level of 15% and a pool of 500 sgRNAs, each sgRNA would be introduced into at least 50 CK19+ epithelial cells within a single pancreas.

To uncover long-tail genes that cooperate with oncogenic KRasG12D and accelerate PDAC development, we injected the experimental and the control AAV-sgRNA libraries into the pancreas of 23 and 13 KC mice, respectively. Next-generation sequencing confirmed efficient AAV transduction of all sgRNAs (Supplementary Fig.2a). Importantly, KC mice transduced with the long-tail PDAC sgRNA library developed pancreatic cancer significantly faster than littermates transduced with the control sgRNA library (31 versus 59 weeks; p<0.0001) (Fig.1b and c). In addition, 13/23 (56%) KC mice transduced with the long-tail PDAC sgRNA library developed liver and/or lung metastasis, while only 1/13 (~8%) littermate mice transduced with the control sgRNA library developed metastasis (Supplementary Fig.2b-e), indicating the existence of strong tumor suppressors within the long-tail of PDAC associated genes.

To identify these PDAC driver genes, we examined the sgRNA representation in 151 tumors. 78% of tumors showed strong enrichment for single sgRNAs, indicating a clonal origin. In contrast, the pancreas of control-transduced mice with multifocal PanINs showed enrichment of several non-template control sgRNAs (Fig.1d). We prioritized genes that were targeted by 2 sgRNAs and knocked out in multiple tumors and/or metastatic foci, resulting in 8 candidate tumor suppressor genes (Fig.1e, Supplementary Data2). These candidates included well-known PDAC tumor suppressor genes, such as Cdkn2a23, Rnf4324, Fbxw725 or NF226, as well as genes with poorly understood function, such as Usp15 and Scaf1.

Pancreatitis is a risk factor for the development of PDAC in humans and cooperates with oncogenic KRas mutations to induce PDAC formation in mice23,27. Therefore, we repeated our screen and treated mice with chronic, low doses of cerulein to induce mild pancreatitis. As expected, cerulein treatment significantly accelerated PDAC development in KC mice transduced with the PDAC sgRNA library (17 versus 32 weeks median survival, p<0.0001), and a trend towards faster PDAC development in KC mice transduced with the control library (Supplementary Fig.2f). In line with the previous screen, Cdkn2a was the top-scoring gene followed by Rnf43 and the newly identified genes, Usp15 and Scaf1 (Supplementary Fig.2g), further supporting their function as strong suppressors of pancreatic cancer in KC mice.

The multi-domain deubiquitinase USP15 regulates diverse processes, such as the p53 tumor suppressor pathway28, MAPK signaling29, Wnt/beta-catenin signaling30, TGF- signaling31,32,33, NfKb signaling32,34,35 and chromosome integrity36,37, either through regulated de-ubiquitination of direct substrates such as MDM2, APC, SMADs or TGF- receptors, or de-ubiquitination-independent functions such as through protein-protein interactions38.

To validate the tumor suppressive function of Usp15, we first injected KC mice individually with one library or one newly designed sgRNA. All transduced mice developed highly proliferative pancreatic tumors with much shorter latencies compared to mice transduced with the non-targeting control sgRNAs (sgCrtl) (Fig.2a). In fact, age-matched control KC mice only exhibited PanINs at the time when USP15 knockout mice exhibit aggressive PDACs (Fig.2b). All tested tumors exhibited efficient CRISRP/Cas9-mediated mutagenesis of Usp15 (Supplementary Fig.3a and b).

A Tumor-free survival of Pdx1-Cre;LSL-KrasG12D;LSL-Cas9-GFP mice injected with CRISPR AAV-sgRNAs targeting the indicated gene or non-targeting control sgRNA (sgCtrl, n=6). Two independent sgRNAs were used (sgUsp15_1 n=9, sgUsp15_2 n=9). Log-Rank test (Mantel-Cox). B Representative H&E images showing multifocal PanINs in sgCtrl transduced pancreas and PADC tumors in sgUsp15 transduced pancreas. Scale bar 100m. C Tumor-free survival of Pdx1-Cre;LSL-KrasG12D mice with the indicated Usp15 genotype where + indicates the wildtype allele and indicates a conditionally deleted allele. KrasG12D +/- Usp15 +/+ (n=12); KrasG12D +/- Usp15 +/- (n=11); KrasG12D +/- Usp15 -/- (n=13). Log-Rank test (Mantel-Cox). D Representative H&E images of mice with the indicated genotype showing multifocal PanINs and PADC tumors. Scale bar 100m. E Cell proliferation curves of KC cells transduced with the indicated sgRNA obtained using the IncuCyte live-cell imaging. Cells were grown for five days and data are expressed as cell confluence percentage (%; meanSD, n=3 independent experiments, Two-way ANOVA (sgUsp15_1 p=3.43e-8: sgUsp15_2 p=4.89e-9), Dunnetts multiple comparison. F Cell proliferation curves of KC cells expressing ubiquitin variants inhibiting Usp15 (Ubv15.1a and Ubv15.1/d) or wildtype ubiquitin (Ubwt) as control. (%; meanSD, n=3 independent experiments, Two-way ANOVA (Ubv15.1a p=2.74e-6: Ubv15.1/d p=2.06e-7), Dunnetts multiple comparison. G Tumor-free survival of NSG (NOD Scid Gamma) mice after orthotopic injection sgCtrl (n=5) or sgUsp15_1/2 (n=5; n=5) KC cells. Two independent sgRNAs were used. Log-Rank test (Mantel-Cox). H Dose-response curves for KPC sgCtrl or sgUsp15 cells treated with the indicated concentration of Olaparib (meanSD, n=3 independent experiments). Two-way ANOVA (sgUsp15_1 p=0.0349: sgUsp15_2 p=0.0431), Dunnetts multiple comparison.

To further confirm the tumor suppressive role and rule out any confounding effect of Cas9 endonuclease expression, we generated conditional Usp15fl/fl; KRasG12D; Pdx1-Cre. This conventional knock-out approach recapitulated our CRISPR/Cas9 findings (Fig.2c and d), validating our in vivo CRISPR approach. Interestingly, Usp15fl/+ heterozygous mice also manifested significantly shorter disease-free survival (Fig.2c). To assess whether tumor development was due to Usp15 loss of heterozygosity, we used fluorescence-activated cell sorting (FACS) to isolate tumor cells from Usp15 homozygous, heterozygous and wild-type KRasG12D tumors. Western Blot analysis revealed Usp15 expression in Usp15 heterozygous tumor cells, albeit at a reduced level compared to control tumors (Supplementary Fig.3c), indicating Usp15 functions as a haploinsufficient tumor suppressor.

Next, we established primary PDAC cell lines from KC mice as well as KC mice with concomitant expression of the hotspot p53R270H mutant (KPC) and used CRISPR/Cas9 to knock-out Usp15 (Supplementary Fig.3d). Loss of Usp15 significantly increased proliferation of these KC cells (Fig.2e), while it did not affect KPC cells (Supplementary Fig.3e), presumably, because those cells are at the maximal proliferation rate. Similar results were obtained using ubiquitin variants (UbVs) that bind and block the catalytic domain of Usp1538, indicating that this tumor suppressive function is de-ubiquitination dependent (Fig.2f). Upon orthotopic injection, Usp15 knock-out KC cells also formed allograft tumor faster than non-targeting control cells (Fig.2g). Together, these data show that Usp15 regulates tumor cell proliferation in a cell-autonomous manner and loss of Usp15 increases a cells ability to form allograft tumors.

Consistent with a previous report36, we also found that loss of Usp15 sensitizes pancreatic cancer cells to Poly-(ADP-ribose) polymerase inhibition (PARPi) by Olaparib. This increased drug sensitivity was stronger in KPC cells than KC cells and was also seen in response to Gemcitabine, one of the most commonly used chemotherapies to treat pancreatic cancer (Fig.2h and Supplementary Fig3f, Fig.4a and b). KC cells were overall more sensitive to Gemcitabine likely due to the intact p53 response (Supplementary Fig3g). Importantly, loss of USP15 also sensitized allograft tumors in vivo towards Olaparib treatment (Supplementary Fig.4c). In addition, we found that Olaparib and Gemcitabine treatment significantly increases expression of Usp15 in KC and KPC cells (Supplementary Fig.4d). In line with its haploinsufficient tumorigenic effect, heterozygous loss of Usp15 also significantly increased proliferation and sensitized to Olaparib treatment, but not as pronounced as complete Usp15 loss (Supplementary Fig.4e and f). As such, Usp15 appears to function as a double-edged sword in pancreatic cancer, where the loss of Usp15 enhances tumor progression in the initial stages of tumorigenesis but sensitizes to certain treatment regimens in the later stages.

Given the wide range of USP15 substrates and USP15-regulated pathways with well-known functions in cancer, we set out to elucidate USP15s exact role in PDAC suppression. First, we transcriptionally profiled primary KC cells transduced with sgRNAs targeting Usp15 or non-template controls sgRNAs. Inactivation of Usp15 resulted in dramatic changes in gene expression compared to scrambled control KrasG12D tumor cells (794 differentially expressed genes (DEG), false discovery rate (FDR, Benjamini-Hochberg)<0.05 and absolute log2 fold-change > 1, Fig.3a and Supplementary Data3). Gene set enrichment analyses (GSEA) revealed significantly upregulated gene sets associated with xenobiotic detoxification, glutathione metabolism, anabolic processes, and oxidative phosphorylation (Fig.3b and Supplementary Data3). These findings are in line with USP15s known role in negatively regulating NRF239 (encoded by the NFE2L2 gene), the master regulator of glutathione metabolism and the redox balance of a cell. In addition, NRF2 expression is induced by oncogenic KRAS and known to stimulate proliferation and suppress senescence of PDAC cells40. Indeed, Usp15 knock-out cells exhibited significantly increased levels of Nrf2 (Supplementary Fig.5a).

A Volcano Blot showing differential expressed genes between Usp15-knockout compared to sgCtrl control KC cells. Wald test and Benjamini-Hochberg (BH)-adjusted P-value. Two independent sgRNAs, two biological duplicates. B Bar graph showing gene set enrichment analysis (GSEA) of Usp15-knockout compared to sgCtrl control KC cells. GSEA nominal p-values. Two independent sgRNAs, two biological duplicates. C GSEA plots and Heatmaps of log2 counts per million for selected differentially expressed pathways and genes in sgUsp15 versus sgCtrl control KC cells. GSEA nominal p-values. Two independent sgRNAs, two biological duplicates. D Expression levels of genes related to TNF signaling evaluated by RT-qPCR. Results were normalized with Gapdh and are expressed in fold change compared to Ctrl (meanSEM, n=3 independent experiments). Cells were incubated with 10ng/mL TNF-for 30min. Two-sided T-test, Rel-B p=0.043; TRAF-1 p=0.037/p=0.034; NFKB1 p=0.036; Rel-B p=0.042; TRAF-1 p=0.039; CXCL2 p=0.028; CXCL3 p=0.047/p=0.043; NFKB1 p=0.038/p=0.040; NFKB2 p=0.039/p=0.043.

GSEA also revealed depleted genes sets associated with inflammatory responses, TNF, TGF and p53 signaling (Fig.3b-d and Supplementary Fig.5b), all pathways with well-known tumor suppressive function in PDAC development17,41. Quantitative RT-PCR confirmed reduced expression of TNF and TGF responsive genes at baseline as well as TNF/TGF-stimulated conditions (Fig.3d and Supplementary Fig.5c). In addition, loss of USP15 reduced TNFinduced cell death and TGF-induced migration (Supplementary Fig.5d and e). Together, these data indicate that Usp15 functions as a strong haploinsufficient PDAC tumor suppressor potentially by regulating tumor suppressive cytokine signaling pathway.

Our second new hit, SCAF1 (SR-Related CTD Associated Factor 1), is a member of the human SR (Ser/Arg-rich) superfamily of pre-mRNA splicing factors. It interacts with the CTD domain of the RNA polymerase II (RNAPII) and is thought to be involved in pre-mRNA splicing42. Its close homologs SCAF4 and SCAF8 were recently shown to be essential for correct polyA site selection and RNAPII transcriptional termination in human cells43. SCAF1 was also one of the top-scoring hits in a screen for genes that can restore homologous recombination in BRCA1-deficient cells and thus conferred resistance to PARP inhibition44. However, the molecular function of SCAF1 remains completely elusive.

First, we validated the tumor suppressive function of Scaf1 by injecting KC mice individually with one library or one newly designed sgRNA. All transduced mice developed highly proliferative pancreatic cancer with much shorter latencies compared to mice transduced with the non-targeting control sgRNAs (Fig.4a, b). Of note, both Scaf1 sgRNAs induced high CRISPR/Cas9-mediated mutagenesis and resulted in significantly reduced Scaf1 mRNA expression (Supplementary Fig.6a, b). Similar to Usp15 knockout cells, we also found that primary Scaf1 knockout KC cells exhibited increased proliferation in culture and formed tumors faster when injected orthotopically into mice compared to scrambled control KC cells (Fig.4c and d). Scaf1 knockout cells also exhibited significantly increased sensitivity to Olaparib in vitro and in vivo (Fig.4e and Supplementary Fig.6c and d), again phenocopying Usp15 knockout cells.

A Tumor-free survival of Pdx1-Cre;LSL-KrasG12D;LSL-Cas9-GFP mice injected with CRISPR AAV targeting the indicated gene or non-targeting control sgRNA (sgCtrl n=6). Two independent sgRNAs were used (sgScaf1_1 n=8, sgScaf1_2 n=7). Log-Rank test (Mantel-Cox). B Representative H&E images showing multifocal PanINs in sgCtrl-transduced pancreas and PADC tumors in sgScaf1-transduced pancreas. Scale bar 100m. C Cell proliferation curves of KC sgCtrl and sgScaf1 cells were obtained using the IncuCyte live-cell imaging and data are expressed as cell confluence percentage (%; meanSD, n=3 independent experiments). Two-way ANOVA (sgScaf1_1 p=0.0039: sgScaf1_2 p=0.00042), Dunnetts multiple comparison. D Tumor-free survival of NSG mice orthotopically injected with sgCtrl (n=5) or sgScaf1_1/2 (n=5; n=5) KC cells. Two independent sgRNAs were used. Log-Rank test (Mantel-Cox). E Dose-response curves for KPC sgCtrl or sgScaf1 cells treated with the indicated concentration of Olaparib (meanSD, n=3 independent experiments). Two-way ANOVA (sgScaf1_1 p=0.0084: sgScaf1_2 p=0.0028), Dunnetts multiple comparisons. F Representative Western Blot of Usp15 in KC cells transduced with the indicated sgRNAs and treated as indicated. This experiment was repeated independently two times with similar results. G Cell growth curves of KC sgCtrl and sgScaf1cells expressing the listed isoform of USP15 or an empty vector (EV). Data are expressed as cell confluence percentage (%; meanSD, n=3 independent experiments); two-way ANOVA (sgScaf1+EV p=0.0342), Dunnetts multiple comparison. Dose-response curves for KC sgCtrl and sgScaf1 cells expressing the listed isoforms of USP15 or EV and treated with Olaparib. (%; meanSD, n=3 independent experiments; two-way ANOVA (sgScaf1+EV p=0.00129), Sidak multiple comparison H Tumor-free survival of NSG mice orthotopically injected with sgCtrl (n=5) or sgScaf1 KC cells expressing the listed isoforms of USP15 (n=5: n=5) or EV (n=5; n=5). Log-Rank test (Mantel-Cox).

Interestingly, we found a connection between Scaf1 and Usp15. Scaf1 knockout cells exhibited reduced expression of full-length Usp15 (molecular weight of ~125kDa) and showed expression of a 25kDa short Usp15 isoform under homeostatic as well as Olaparib and gemcitabine treatment (Fig.4f and Supplementary Fig.6e and f). SCAF1 KO tumors also exhibited lower levels of full-length USP15 (Supplementary Data Fig.6g). To examine a potential function of this truncated isoform, we cloned and transduced the long and the short isoforms into primary Usp15 knock-out KC cells (Supplementary Fig.6h). While full-length Usp15 was able to supress the hyperproliferative phenotype of Usp15 knock-out cells, the short isoform failed to suppress the cell proliferation (Supplementary Fig.7a). Similarly, re-expressing the full-length but not the short Usp15 isoform reversed the sensitivity of Usp15 knock-out KC cells to Olaparib and gemcitabine (Supplementary Fig.7b). In addition, overexpression of the full-length or the short Usp15 isoform did not alter proliferation of wildtype KC cells (Supplementary Fig.7c), indicating that the short isoform does not exhibit dominant negative functions. However, expression of the long but not the short Usp15 isoform or a catalytically-dead USP15 isoform suppressed the hyperproliferation and Olaparib sensitivity as well as the increased in vivo tumorigenesis of Scaf1 knock-out cells (Fig.4g and h and Supplementary Fig.7c-f). Together these data indicate that the short isoform has no tumor suppressive functions or alters the response to PARP inhibition and that Scaf1s tumor suppressive function is at least in part routed by regulating the expression of full-length Usp15.

To further elucidate the effects of Scaf1, we transcriptionally profiled Scaf1 knockout KC cells. Inactivation of Scaf1 resulted in 625 differentially expressed genes (DEG) (false discovery rate (FDR)<0.05 and absolute log2 fold-change > 1, Fig.5a and Supplementary Data3) compared to scrambled control KrasG12D tumor cells. GSEA revealed significantly upregulated gene sets associated with nucleotide metabolism, glutathione metabolism, microtubule polymerization, and oxidative phosphorylation as well as downregulation gene sets associated with TNF signaling, one-carbon metabolism, xenobiotic catabolic processes, mTorc1/mTOR signaling, hypoxia and p53 signaling (Fig.5b and Supplementary Fig.7g). In addition, we found a trend towards downregulated TGF signaling (Fig.5b and Supplementary Data3), reminiscent of the pathways altered in Usp15 knock-out cells.

A Volcano Blot showing differential expressed genes between Scaf1-knockout compared to control KC cells. Wald test and Benjamini-Hochberg (BH)-adjusted P-value. Two independent sgRNAs, two biological duplicates. B Bar graph showing gene set enrichment analysis of Scaf1-knockout compared to control KC cells. GSEA nominal p-values. Two independent sgRNAs, two biological duplicates. C Bar graph showing gene set enrichment analysis of Usp15-knockout and Scaf1-knockout compared to sgCtrl control KC cells treated with Olaparib (1M). GSEA nominal p-values. Two independent sgRNAs, two biological duplicates. D Expression levels of genes related to HH signaling evaluated by RT-qPCR in the indicated KC cell lines. Results were normalized with Gapdh and are expressed in fold change to CTRL (meanSEM, n=3 independent experiments). Cells were treated with 100nM Smoothened Agonist (SAG) and 1M Olaparib. Two-sided T-test, for sgUSP15: NRP2 p=0.021/p=0.018; PTCH1 p=0.037/p=0.033; GLI1 p=0.033; NRP2 p=0.042/p=0.037; for sgScaf1: PTCH1 p=0.046; PTCH2 p=0.040/p=0.042/p=0.033; GLI1 p=0.037/p=0.031; NRP2 p=0.042.

Lastly, we set out to elucidate how Usp15 and Scaf1 regulate the response of pancreatic cancer cells to PARP inhibition. Interestingly, transcriptional profiling and GSEA following Olaparib treatment revealed that both Usp15 and Scaf1 knock-out cells, exhibited downregulation of hedgehog signaling, TGF signaling and axon guidance by netrin as well as upregulation of glycolysis as the top dysregulated pathways compared to Olaparib-treated control KC cells (Fig.5c and Supplementary Data4). Together, this indicates a common mechanism leading to increased sensitivity to PARP inhibition shared between Usp15 and Scaf1 knock-out cells. Indeed, quantitative RT-PCR confirmed reduced expression of hedgehog target genes at baseline as well as upon sonic hedgehog stimulation (Fig.5d). Thus, Scaf1 and Usp15 knockout cells share several alterations such as upregulated TNF signaling and downregulated TGF, hedgehog and p53 signaling but also several distinct pathways.

To extend our findings from mouse to human cancers, we analyzed 295 PDAC samples from The Cancer Genome Atlas45,46,47. Mutations and homozygous deletion of USP15 and Scaf1 are rare as expected for long-tail mutation and were found in only 2.4% and 1.4% of PDAC samples, respectively. However, an additional 25% and 13% of PDAC cases showed shallow deletions of USP15 and SCAF1, respectively, indicative of heterozygous loss of these genes (Fig.6a). Focal USP15 and SCAF1 copy-number losses have been identified in independent large-scale genome studies48,49. In addition, allelic copy number loss also coincided with reduced expression of USP15 and SCAF1 and patients with deep or shallow USP15 or SCAF1 deletions showed a significant trend towards a shorter overall survival (Fig.6b and Supplementary Fig.8a). Given our genetic and biochemical data linking SCAF1 and USP15, we next considered patients with deep or shallow USP15 or SCAF1 deletions as a group (=37% of patients) and found a significantly shorter overall survival (Supplementary Fig.8b). This raises the possibility that USP15 and potentially also SCAF1 function in a haploinsufficient manner, which is in line with the increased tumorigenesis found in the Usp15fl/+; KRasG12D; Pdx1-Cre mice.

A Oncoprint of the indicated genes in PDAC samples (n=293, TCGA). B Kaplan-Meier survival analyses of PDAC patients with deep or shallow USP15 or SCAF1 deletion. (n=293, TCGA) Log-Rank test (Mantel-Cox). C Tumor-free survival of NSG mice orthotopically injected with sgCtrl (n=5), sgUsp15_1/2 (n=5; n=5) or sgSCAF1_1/2 (n=5; n=5) PANC-1 cells. Two independent sgRNAs were used. Log-Rank test (Mantel-Cox) D Dose-response curves for sgCtrl, sgUsp15 or sgSCAF1 PANC-1 cells treated with Olaparib. (%; meanSD, n=3 independent experiments) two-way ANOVA (sgUsp15_1 p=0.0242; sgUsp15_2 p=0.0387; sgScaf1_1 p=0.0281; sgScaf1_2 p=0.0371), Dunnetts multiple comparison. E sgUSP15 and sgOR2W5 PDO Competition Assay. sgUSP15 and control sgOR2W5 patient-derived organoids were disassociated into single cells and mixed in a 20:80% ratio. Organoid cultures were passaged, and a sample was collected every ~7 days. Percentage of DNA indels is tracked overtime by sanger-sequencing and TIDE analysis.

Next, we assessed the expression of USP15 in 4 human pancreatic cancer cell lines. While, PANC1 and HPAFII exhibited expression of the small as well as the long USP15 isoform, MiaPACA2 and BXPC3 cells only exhibited low-level expression of the long USP15 isoform, indicating that USP15 is also downregulated in some human pancreatic cancer cell lines (Supplementary Fig.8c).

To functionally test USP15 and SCAF1, we genetically ablated these genes in human PANC1 cells (Supplementary Fig.8d and e). Importantly, genetic ablation of SCAF1 resulted in increased expression of the short USP15 isoform, indicating that this mechanism is conserved from mouse to human cells (Supplementary Fig.8f). Similarly, to our autochthonous mouse experiments, we also found that loss of USP15 or SCAF1 in PANC1 cells resulted in accelerated tumorigenesis and increased sensitivity to Olaparib and Gemcitabine (Fig.6c, d and Supplementary Fig.8g). We also observed increased NRF2 protein levels in USP15 knockout PANC1 cells, which showed further elevated upon inhibition of TXNRD1/2 and antioxidant imbalance by auranofin treatment50 (Supplementary Fig.8h), akin to our findings in mouse KC cells. USP15 knockout PANC1 cells also exhibited increased sensitivity to auranofin treatment (Supplementary Fig.8i).

Lastly, we genetically ablated USP15 in patient-derived organoids (PDOs) from 3 different pancreatic cancer patients using Cas9 ribonucleotide particles. We set up competitive growth assays to assess the relative fitness of USP15 knockout PDOs compared to OR2W5 knockout PDOs. Of note, the OR2W5 olfactory receptor is not expressed in pancreatic PDOs and thus serves as control. We mixed the USP15 knockout and the OR2W5 knockout PDOs at a 1:4 ratio and followed their relative growth by quantifying the percent of USP15 and OR2W5 mutations over time using Sanger sequencing. Within ~10 passages, we observed that the PDO cultures were almost completely taken over by USP15 knockout cells (Fig.6e). Together, these data demonstrate the tumor suppressive function of USP15 and SCAF1 in pancreatic cancer by modulating several important signaling pathways and that loss of USP15 and SCAF1 sensitizes to Gemcitabine and Olaparib.

Read more from the original source:
In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer - Nature.com

Comments Closed|

CRISPR-based paper test could improve influenza testing access, outbreak surveillance – LabPulse

June 25th, 2024

Researchers from the Broad Institute of MIT, Harvard, and Princeton University have developed a low-cost paper strip test that uses CRISPR to distinguish between the two main types of seasonal influenza, A and B, as well as subtypes H1N1 and H3N2.

Furthermore, the test can also identify strains that resist antiviral treatment and could potentially be adapted to detect swine and avian flu strains, including H5N1, currently causing an outbreak in cattle.

Results from the test, described in an article in The Journal of Molecular Diagnostics, show that the test, which was designed to be rapid, affordable, and easy to deploy at point-of-need is also accurate at distinguishing the types and subtypes of influenza, achieving results in 100% concordance with traditional polymerase chain reaction (PCR) assays.

The test is based on a technology called SHINE, which was developed in 2020 by the lab of co-author Pardis Sabeti, an institute member at the Broad and a professor at Harvard University and the Harvard T.H. Chan School of Public Health, as well as a Howard Hughes Medical Institute investigator. SHINE uses CRISPR enzymes to identify specific sequences of viral RNA in samples.

The teams aim was to create low-cost, rapid tests that could be deployed in clinics or in the field rather than in hospitals or diagnostic labs, and that didnt require expensive equipment to run. Accessible, efficient testing technology not only improves clinical care, but also may potentially improve outbreak management, making it easier for scientists to collect samples strategically to better monitor viral spread.

In contrast to typical diagnostic assays such as PCR which may require lengthy processing times, extensive training for personnel, and specialized equipment, SHINE testing can be performed in about 90 minutes at room temperature, and only requires an inexpensive heat block to warm the reaction.

The researchers first used SHINE to test for SARS-CoV-2, later adapting it to distinguish between the Delta and Omicron variants. They began adapting the assay to test for influenza viruses in 2022.

In the future, the team said in a story from the Broad Institute, the assay could be adapted to distinguish between different viruses with similar symptoms, such as influenza and SARS-CoV-2.

See more here:
CRISPR-based paper test could improve influenza testing access, outbreak surveillance - LabPulse

Comments Closed|

Scientists create gene-editing tool that may revolutionize DNA engineering – TweakTown

June 25th, 2024

A team of scientists created a new gene-editing tool that they claim is more accurate than the industry standard, CRISPR.

VIEW GALLERY - 2 IMAGES

Researchers from the University of Sydney, Australia, developed what is called SeekRNA, a new gene-editing tool that uses a programmable ribonucleic acid (RNA) strand capable of identifying and inserting itself into specific sites in genetic sequences. The team behind the project is being led by Dr. Sandro Ataide in the School of Life and Environmental Sciences, and their findings have already been published in Nature Communications.

The team explained that while CRISPR is the industry standard when it comes to genetic engineering, having revolutionized multiple industries such as medicine, agriculture, and biotechnology, it doesn't come without any problems. According to Dr. Ataide, SeekRNA differentiates itself from CRISPR in various ways, such as by not requiring any extra components to be cut and pasted into genetic sequences. SeekRNA is a stand-alone cut-and-paste tool that has higher accuracy.

Furthermore, CRISPR relies on creating a break in both strands of target DNA, which is the double-helix strand that commonly depicts a DNA sequence. While CRISPR is certainly impressive in its own right it requires the use of proteins or the DNA repair machinery to insert the new DNA sequence into its designated location. This process can produce errors in the code.

"SeekRNA can precisely cleave the target site and insert the new DNA sequence without the use of any other proteins. This allows for a much cleaner editing tool with higher accuracy and fewer errors," said Dr. Ataide

"We are tremendously excited by the potential for this technology. SeekRNA's ability to target selection with precision and flexibility sets the stage for a new era of genetic engineering, surpassing the limitations of current technologies," Dr Ataide said.

"With CRISPR you need extra components to have a 'cut-and-paste tool', whereas the promise of seekRNA is that it is a stand-alone 'cut-and-paste tool' with higher accuracy that can deliver a wide range of DNA sequences."

Read more:
Scientists create gene-editing tool that may revolutionize DNA engineering - TweakTown

Comments Closed|